[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 261
1. Landgren O, Turesson I, Gridley G, Caporaso NE: Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease. Arch Intern Med; 2007 Jun 11;167(11):1189-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Among 832 294 African American and 3 668 983 white male veterans with at least 1 hospital admission in US Veterans Affairs hospitals and up to 27 years of follow-up, we identified a total of 1525 patients with Gaucher disease; 11.7% were African Americans.
  • When we stratified our analyses by race, risks were similar for whites (RR, 0.89; 95% CI, 0.74-1.07 [n = 120]) and African Americans (RR, 1.00; 95% CI, 0.61-1.64 [ n = 17]).
  • Patients with Gaucher disease had an elevated risk for non-Hodgkin lymphoma (RR, 2.54; 95% CI, 1.32-4.88 [n = 9]), malignant melanoma (RR, 3.07; 95% CI, 1.28-7.38 [n = 5]), and pancreatic cancer (RR, 2.37; 95% CI, 1.13-4.98 [n = 7]).
  • CONCLUSION: We found 2- to 3-fold risks of non-Hodgkin lymphoma, malignant melanoma, and pancreatic cancer in patients with Gaucher disease, but no significant association between Gaucher disease and cancer in general or with other specific malignancies such as multiple myeloma.
  • [MeSH-minor] African Continental Ancestry Group / statistics & numerical data. Cohort Studies. European Continental Ancestry Group / statistics & numerical data. Follow-Up Studies. Hospitals, Veterans. Humans. Male. Middle Aged. Registries. Risk Assessment. United States / epidemiology


2. Niv Y, Koren R: 13C-urea breath test for success of Helicobacter pylori eradication: study of 5885 Israeli patients. Dig Dis Sci; 2005 Aug;50(8):1513-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori (Hp) infection is highly prevalent in many countries and may cause gastritis, peptic ulcer disease, gastric cancer, and lymphoma.
  • The only good prognostic factor for successful eradication was Israeli origin, while European-American and Asian-African origin, recurrence of symptoms, a history of duodenal ulcer, and chronic proton pump inhibitor (PPI) use did not favor successful eradication.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aliment Pharmacol Ther. 2001 Jul;15(7):1023-9 [11421878.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):790-4 [9149186.001]
  • [Cites] Harefuah. 1999 Oct;137(7-8):272-4, 352, 351 [12415967.001]
  • [Cites] N Engl J Med. 1998 Dec 24;339(26):1869-74 [9862941.001]
  • [Cites] Gastroenterol Clin North Am. 2000 Sep;29(3):559-78 [11030073.001]
  • [Cites] Am J Gastroenterol. 1996 Jan;91(1):85-8 [8561150.001]
  • [Cites] Gut. 1998 Jul;43 Suppl 1:S47-50 [9764040.001]
  • [Cites] Mol Biotechnol. 1999 Feb;11(1):85-92 [10367284.001]
  • [Cites] Scand J Clin Lab Invest. 1998 Feb;58(1):19-27 [9516653.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Feb;16(2):167-80 [11860399.001]
  • [Cites] Clin Infect Dis. 1997 Nov;25(5):1038-43 [9402353.001]
  • [Cites] Gut. 1999 Jul;45 Suppl 1:I18-22 [10457031.001]
  • [Cites] Am J Gastroenterol. 1999 Nov;94(11 Suppl):S11-6 [10565604.001]
  • [Cites] J Gastroenterol. 1997 Feb;32(1):24-7 [9058291.001]
  • [Cites] Helicobacter. 1998 Jun;3(2):93-6 [9631306.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):2057-62 [10430397.001]
  • [Cites] Yale J Biol Med. 1998 Mar-Apr;71(2):135-41 [10378359.001]
  • [Cites] J Antimicrob Chemother. 2002 Jun;49(6):1023-6 [12039897.001]
  • (PMID = 16110844.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents
  •  go-up   go-down


3. Plancoulaine S, Gessain A, Tortevoye P, Boland-Auge A, Vasilescu A, Matsuda F, Abel L: A major susceptibility locus for HTLV-1 infection in childhood maps to chromosome 6q27. Hum Mol Genet; 2006 Nov 15;15(22):3306-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) is a human oncoretrovirus causing adult T-cell leukemia/lymphoma and chronic neuromyelopathy.
  • We previously showed by segregation analysis that a dominant gene controls HTLV-1 infection through breast-feeding in children of African origin.
  • Five pedigrees of African origin with HTLV-1 seropositive children were included in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17028113.001).
  • [ISSN] 0964-6906
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCR6 protein, human; 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 2; 0 / Receptors, CCR6; 0 / Receptors, Chemokine
  •  go-up   go-down


Advertisement
4. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H: Part I: Cancer in Indigenous Africans--burden, distribution, and trends. Lancet Oncol; 2008 Jul;9(7):683-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The top five cancers in males--Kaposi's sarcoma (constituting 12.9% of all cancers in males) and cancer of the liver (14.8%), prostate (9.5%), bladder (6.1%), and non-Hodgkin lymphoma (5.7%)--and in females--cancer of the cervix (constituting 23.3% of all cancers in females) and breast (19.2%), Kaposi's sarcoma (5.1%), cancer of the liver (5.0%), and non-Hodgkin lymphoma (3.7%)--are discussed in detail.
  • [MeSH-major] African Continental Ancestry Group / statistics & numerical data. Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18598933.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


5. Kpolugbo J, Alili U, Abubakar M: Intra-abdominal gossypiboma: a report of two cases and a review of literature. Cent Afr J Med; 2010 Jan-Apr;56(1-4):17-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case report of a 27-year-old trader with intra-abdominal foreign body is presented to highlig at the similarity in presentation with abdominal lymphoma and the need to explore carefully masses in the abdominal cavity especially in patients who have had surgery in the past.
  • Prompt diagnosis and treatment ameliorates the patients suffering and brings them back to life.
  • [MeSH-major] Foreign-Body Reaction / diagnosis
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Diagnosis, Differential. Female. Humans. Surgical Sponges / adverse effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23457869.001).
  • [ISSN] 0008-9176
  • [Journal-full-title] The Central African journal of medicine
  • [ISO-abbreviation] Cent Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Zimbabwe
  •  go-up   go-down


6. Mwanda WO, Whalen C, Remick SC: Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa. East Afr Med J; 2005 Sep;82(9 Suppl):S133-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma and emerging therapeutic strategies for EBV and AIDS-associated lymphoproliferative diseases in East Africa.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Burkitt Lymphoma / drug therapy. Epstein-Barr Virus Infections / drug therapy. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / drug therapy. Lymphoproliferative Disorders / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619688.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Grant] United States / PHS HHS / / A136219; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Kenya
  •  go-up   go-down


7. De Falco G, Leucci E, Lenze D, Piccaluga PP, Claudio PP, Onnis A, Cerino G, Nyagol J, Mwanda W, Bellan C, Hummel M, Pileri S, Tosi P, Stein H, Giordano A, Leoncini L: Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood; 2007 Aug 15;110(4):1301-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors.
  • Burkitt lymphoma (BL) is a B-cell tumor whose characteristic gene aberration is the translocation t(8;14), which determines c-myc overexpression.
  • We then monitored their expression in primary tumors of endemic BL as well, demonstrating that their expression resembled those of the BL cell lines.
  • [MeSH-major] Biomarkers, Tumor / genetics. Burkitt Lymphoma / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Mutation / genetics. Retinoblastoma-Like Protein p130 / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485552.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA60999
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RBL2 protein, human; 0 / Retinoblastoma-Like Protein p130
  •  go-up   go-down


8. Chuang GS, Wasserman DI, Byers HR, Demierre MF: Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy. J Am Acad Dermatol; 2008 Nov;59(5 Suppl):S121-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Arthritis, Rheumatoid / drug therapy. Hypopigmentation / etiology. Immunoglobulin G / adverse effects. Lymphoma, T-Cell, Cutaneous / complications. Mycosis Fungoides / etiology. Skin Neoplasms / complications
  • [MeSH-minor] African Continental Ancestry Group. Etanercept. Female. Humans. Middle Aged. Receptors, Tumor Necrosis Factor

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19119122.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; OP401G7OJC / Etanercept
  •  go-up   go-down


9. Adhvaryu MR, Reddy N, Parabia MH: Anti-tumor activity of four Ayurvedic herbs in Dalton lymphoma ascites bearing mice and their short-term in vitro cytotoxicity on DLA-cell-line. Afr J Tradit Complement Altern Med; 2008 Jun 18;5(4):409-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor activity of four Ayurvedic herbs in Dalton lymphoma ascites bearing mice and their short-term in vitro cytotoxicity on DLA-cell-line.
  • Curcuma longa L., Ocimum sanctum L., Tinospora cordifolia (Wild) Miers ex Hook.f & Thomas and Zizyphus mauritiana Lam. were evaluated using Dalton Lymphoma ascites (DLA) tumor model in Swiss Albino mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Int. 1992 Dec;28(4):735-44 [1482409.001]
  • [Cites] World J Gastroenterol. 2007 Jun 21;13(23):3199-205 [17589898.001]
  • [Cites] J Ethnopharmacol. 1986 Nov;18(2):133-41 [3560991.001]
  • [Cites] Indian J Exp Biol. 1995 Mar;33(3):205-8 [7601491.001]
  • [Cites] Planta Med. 1994 Apr;60(2):106-9 [8202557.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):743-9 [8625175.001]
  • [Cites] J Ethnopharmacol. 1997 Oct;58(2):89-95 [9406896.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2323-7 [9622066.001]
  • [Cites] Pharmacol Res. 1998 Aug;38(2):107-10 [9721597.001]
  • [Cites] Oral Oncol. 1999 Jan;35(1):112-9 [10211319.001]
  • [Cites] Phytother Res. 1999 Jun;13(4):275-91 [10404532.001]
  • [Cites] J Ethnopharmacol. 2000 Nov;73(1-2):81-5 [11025142.001]
  • [Cites] J Ethnopharmacol. 2000 Dec;73(3):461-70 [11091000.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):363-98 [12680238.001]
  • [Cites] Planta Med. 2003 Aug;69(8):692-5 [14531016.001]
  • [Cites] J Ethnopharmacol. 2004 Jan;90(1):155-60 [14698524.001]
  • [Cites] J Pharmacol Sci. 2004 Feb;94(2):177-84 [14978356.001]
  • [Cites] Biol Pharm Bull. 2004 Nov;27(11):1883-6 [15516743.001]
  • [Cites] Pharmacol Res. 2005 Jan;51(1):19-30 [15519531.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Jan;83(1):67-75 [16427690.001]
  • [Cites] Indian J Exp Biol. 1990 Nov;28(11):1008-11 [2283166.001]
  • (PMID = 20161965.001).
  • [ISSN] 2505-0044
  • [Journal-full-title] African journal of traditional, complementary, and alternative medicines : AJTCAM
  • [ISO-abbreviation] Afr J Tradit Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Other-IDs] NLM/ PMC2816583
  • [Keywords] NOTNLM ; Anti-tumor activity / Curcuma longa / Cytotoxicity / DLA cell line / Ocimum sanctum / Tinospora cordifolia / Zizyphus mauritiana
  •  go-up   go-down


10. Swinney RM, Hsu SC, Hirschman BA, Chen TT, Tomlinson GE: MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia; 2005 Nov;19(11):1996-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia.
  • [MeSH-major] Nuclear Proteins / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adolescent. African Continental Ancestry Group / genetics. Age of Onset. Child. Cohort Studies. DNA, Neoplasm. European Continental Ancestry Group / genetics. Female. Genes, p53. Hispanic Americans / genetics. Humans. Male. Promoter Regions, Genetic / genetics. Proto-Oncogene Proteins c-mdm2

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167062.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


11. Bidegain F, Berry A, Alvarez M, Verhille O, Huguet F, Brousset P, Pris J, Marchou B, Magnaval JF: Acute Plasmodium falciparum malaria following splenectomy for suspected lymphoma in 2 patients. Clin Infect Dis; 2005 Jun 1;40(11):e97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute Plasmodium falciparum malaria following splenectomy for suspected lymphoma in 2 patients.
  • Two black African immigrants, with no history of recent travel outside France, received a diagnosis of a malignant lymphoproliferative disorder and splenomegaly, and they subsequently underwent splenectomy.
  • A few weeks after surgery, both patients experienced an acute episode of Plasmodium falciparum malaria, so the initial diagnosis was corrected retrospectively and changed to hyperreactive malarial splenomegaly.
  • [MeSH-major] Malaria, Falciparum / diagnosis. Splenectomy
  • [MeSH-minor] Adult. Cameroon. Central African Republic. Emigration and Immigration. France. Humans. Splenomegaly / diagnosis. Splenomegaly / parasitology. Splenomegaly / surgery

  • Genetic Alliance. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15889352.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Kanduma EG, Mukuria JC, Mwanda OW: Serum total sialic acid and Hanganutziu-Deicher antibody in normals and in cancer patients. East Afr Med J; 2007 May;84(5):207-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinoma patients constituted 54%, sarcoma 12.1%, lymphoma 16.4% and 17.4% had other types of tumours.
  • HD antibody readings was significantly higher in carcinomas (p = 0.017) compared to those of sarcomas and lymphomas.
  • [MeSH-major] Antibodies, Heterophile / blood. Biomarkers, Tumor. Carcinoma / diagnosis. Lymphoma / diagnosis. N-Acetylneuraminic Acid / blood. Sarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892194.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antibodies, Heterophile; 0 / Biomarkers, Tumor; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


13. Kidmas AT, Ugwu BT, Manasseh AN, Iya D, Opaluwa AS: Male breast malignancy in Jos University Teaching Hospital. West Afr J Med; 2005 Jan-Mar;24(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Poor level of awareness often results in late presentation and delayed diagnosis in our environment.
  • There were 23 (88.5%) carcinomas, 2 (7.7%) fibrosarcomas and a case of Hodgkin's lymphoma.
  • The only case of Hodgkin's lymphoma had chemotherapy.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Hospitals, University / utilization

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909708.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


14. Yone CL, Kube D, Kremsner PG, Luty AJ: Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg; 2006 Jul;100(7):669-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria.
  • Epstein-Barr virus (EBV) and Plasmodium falciparum have overlapping distributions and are thought to have causal interactions, particularly with regard to the aetiology of endemic Burkitt's lymphoma.

  • Genetic Alliance. consumer health - Malaria.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313933.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Cytokines; 0 / DNA, Viral
  •  go-up   go-down


15. Hesseling PB, Molyneux E, Kamiza S, Broadhead R: Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma. Trans R Soc Trop Med Hyg; 2008 Jun;102(6):602-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rescue chemotherapy for patients with resistant or relapsed endemic Burkitt's lymphoma.
  • Patients with endemic Burkitt's lymphoma who failed primary treatment with the Malawi 2002 or 2003 Burkitt's lymphoma treatment protocols, consisting of high frequency cyclophosphamide 40 mg/kg and intrathecal methotrexate, were offered rescue chemotherapy.
  • This simple 15-day chemotherapy schedule salvaged 36% of patients and significantly increased the overall cure rate of our Burkitt's lymphoma patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18417177.001).
  • [ISSN] 0035-9203
  • [Journal-full-title] Transactions of the Royal Society of Tropical Medicine and Hygiene
  • [ISO-abbreviation] Trans. R. Soc. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Baker PS, Gold KG, Lane KA, Bilyk JR, Katowitz JA: Orbital burkitt lymphoma in immunocompetent patients: a report of 3 cases and a review of the literature. Ophthal Plast Reconstr Surg; 2009 Nov-Dec;25(6):464-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital burkitt lymphoma in immunocompetent patients: a report of 3 cases and a review of the literature.
  • PURPOSE: To describe a series of 3 immunocompetent patients with the sporadic form of orbital Burkitt lymphoma and review the outcomes of such patients reported in the scientific literature.
  • Cases of orbital Burkitt lymphoma in immunocompromised and African patients were excluded from the review.
  • RESULTS: Current cases and review of the scientific literature resulted in 16 immunocompetent patients with sporadic orbital Burkitt lymphoma.
  • CONCLUSIONS: Sporadic orbital Burkitt lymphoma occurs in immunocompetent individuals with a wide age range.
  • The large number of patients with central nervous system involvement in our review of the literature supports the role of lumbar puncture and neuroimaging in the workup of all patients with orbital Burkitt lymphoma.
  • [MeSH-major] Burkitt Lymphoma / complications. Immunocompromised Host. Orbital Neoplasms / complications. Paranasal Sinus Neoplasms / complications

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935250.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


17. Lobetti RG: Lymphoma in 3 related Rottweilers from a single household. J S Afr Vet Assoc; 2009 Jun;80(2):103-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma in 3 related Rottweilers from a single household.
  • Over a period of approximately 1 year, 2 sibling Rottweilers and their dam in the same household developed stage IV and stage III lymphoma, respectively.
  • As no obvious environmental trigger could be identified in these dogs, it is speculated that an underlying genetic predisposition could have played a role in the development of lymphoma in these related dogs.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Dog Diseases / genetics. Doxorubicin / therapeutic use. Lymphoma / veterinary

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19831272.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


18. Müller AM, Ihorst G, Mertelsmann R, Engelhardt M: Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol; 2005 Jan;84(1):1-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.
  • While for most cancers incidence and mortality are decreasing, those of non-Hodgkin's lymphoma (NHL) are steadily increasing.
  • Differences in geographic distribution are striking for follicular lymphoma, which is more common in Western countries than elsewhere.
  • Asians have higher rates of aggressive NHL, T-cell lymphomas, and extranodal disease.
  • In the Middle East, high rates of intestinal extranodal disease are observed, whereas in Africa, endemic Burkitt's lymphoma accounts for a substantial proportion.
  • Risks for developing NHL include immunosuppression and a causal link between infectious agents, and lymphomagenesis has also been determined, particularly for human T-cell leukemia/lymphoma virus type 1 (HTLV-1), Epstein-Barr virus (EBV), and Helicobacter pylori infections.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / etiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15480663.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 99
  •  go-up   go-down


19. Rochford R, Feuer G, Orem J, Banura C, Katongole-Mbidde E, Mwanda WO, Moormann A, Harrington WJ, Remick SC: Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Strategies to overcome myelotoxic therapy for the treatment of Burkitt's and AIDS-related non-Hodgkin's lymphoma.
  • OBJECTIVES: To develop effective non-myelotoxic therapies for Burkitt's Lymphoma (BL) and AIDS-related non-Hodgkin's lymphoma.
  • CONCLUSION: Myelotoxic death rates using multi-agent induction chemotherapy approach 25% for endemic Burkitt's lymphoma and range between 20% to 60% for AIDS-related malignancy.
  • Investigations and alternative approaches that lessen or circumvent myelotoxicity of traditional cytotoxic chemotherapy for the management of Burkitt's lymphoma and AIDS-related non-Hodgkin's lymphoma in the resource-constrained setting are warranted.
  • This can be achieved by developing targeted anti-viral and other strategies, such as the use of bryostatin 1 and vincristine, and by developing a preclinical mouse model to frame the clinical rationale for a pilot trial of metronomic therapy for the treatment of Burkitt's and AIDS-related lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy. Macrolides / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619692.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bryostatins; 0 / Macrolides; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine
  • [Number-of-references] 38
  •  go-up   go-down


20. Bliss A, Buriak S: Descriptive epidemiology of non-Hodgkin's lymphoma in Oklahoma: 1997-2003. J Okla State Med Assoc; 2008 Nov;101(11):262-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of non-Hodgkin's lymphoma in Oklahoma: 1997-2003.
  • OBJECTIVE: To describe the incidence of Non-Hodgkin's lymphoma in Oklahoma residents.
  • African Americans had a significantly lower SIR when compared to Whites: 0.72 (0.44-0.79).
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19113066.001).
  • [ISSN] 0030-1876
  • [Journal-full-title] The Journal of the Oklahoma State Medical Association
  • [ISO-abbreviation] J Okla State Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Calvert JG, Slade DE, Shields SL, Jolie R, Mannan RM, Ankenbauer RG, Welch SK: CD163 expression confers susceptibility to porcine reproductive and respiratory syndrome viruses. J Virol; 2007 Jul;81(14):7371-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transient-transfection experiments showed that full-length CD163 cDNAs from PAM, human U937 cells (histiocytic lymphoma), African green monkey kidney cells (MARC-145 and Vero), primary mouse peritoneal macrophages, and canine DH82 (histocytosis) cells encode functional virus receptors.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jan 1;99(1):378-80 [11756196.001]
  • [Cites] J Leukoc Biol. 2006 Apr;79(4):837-45 [16434690.001]
  • [Cites] J Virol Methods. 2002 Jul;104(2):203-16 [12088830.001]
  • [Cites] Vet Q. 2002 Jun;24(2):95-100 [12095084.001]
  • [Cites] FEBS Lett. 2002 Aug 28;526(1-3):93-6 [12208511.001]
  • [Cites] Viral Immunol. 2002;15(4):533-47 [12513925.001]
  • [Cites] Arch Virol. 2003 Jan;148(1):177-87 [12536303.001]
  • [Cites] J Virol. 2003 Aug;77(15):8207-15 [12857889.001]
  • [Cites] Emerg Infect Dis. 2003 Aug;9(8):903-8 [12967485.001]
  • [Cites] Arch Virol. 2003 Dec;148(12):2307-23 [14648288.001]
  • [Cites] Crit Rev Immunol. 2004;24(1):1-37 [14995912.001]
  • [Cites] Vet Immunol Immunopathol. 2004 Dec 8;102(3):143-54 [15507301.001]
  • [Cites] Eur J Immunol. 1993 Sep;23(9):2320-5 [8370408.001]
  • [Cites] Arch Virol. 1993;133(3-4):477-83 [8257302.001]
  • [Cites] J Clin Microbiol. 1993 Dec;31(12):3184-9 [7508455.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Virus Res. 1996 Jun;42(1-2):137-47 [8806181.001]
  • [Cites] Vet Microbiol. 1997 May;56(1-2):9-19 [9228678.001]
  • [Cites] Arch Virol. 1997;142(3):629-33 [9349308.001]
  • [Cites] J Virol. 1998 Jan;72(1):380-7 [9420236.001]
  • [Cites] J Virol. 1998 May;72(5):4520-3 [9557752.001]
  • [Cites] Arch Virol. 1997;142(12):2483-97 [9672608.001]
  • [Cites] Vet Res. 2000 Jan-Feb;31(1):61-9 [10726638.001]
  • [Cites] J Immunol. 2000 Dec 1;165(11):6406-15 [11086079.001]
  • [Cites] Nature. 2001 Jan 11;409(6817):198-201 [11196644.001]
  • [Cites] Virus Genes. 2001 Mar;22(2):209-17 [11324758.001]
  • [Cites] Immunogenetics. 2001 Mar;53(2):170-7 [11345593.001]
  • [Cites] J Gen Virol. 1999 Feb;80 ( Pt 2):297-305 [10073688.001]
  • [Cites] Mol Biol Evol. 2005 Apr;22(4):1024-31 [15659555.001]
  • [Cites] J Gen Virol. 2005 May;86(Pt 5):1441-5 [15831956.001]
  • [Cites] J Am Vet Med Assoc. 2005 Aug 1;227(3):385-92 [16121604.001]
  • [Cites] Immunobiology. 2005;210(2-4):153-60 [16164022.001]
  • [Cites] Mol Biol Evol. 2005 Nov;22(11):2131-4 [16000650.001]
  • [Cites] J Virol. 2006 Jan;80(2):689-96 [16378972.001]
  • [Cites] J Virol. 2002 May;76(9):4312-20 [11932397.001]
  • (PMID = 17494075.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / DNA Primers; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Receptors, Immunologic; 0 / SIGLEC1 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 1; 0 / Siglec1 protein, mouse
  • [Other-IDs] NLM/ PMC1933360
  •  go-up   go-down


22. Kalungi S, Wabinga H, Molven A, Bostad L: Lymphomas diagnosed in Uganda during the HIV/AIDS pandemic. East Afr Med J; 2009 May;86(5):226-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomas diagnosed in Uganda during the HIV/AIDS pandemic.
  • BACKGROUND: There are numerous reports from different countries documenting a change in frequency and profile of lymphomas after the onset of the HIV/AIDS pandemic.
  • In Uganda little is known concerning the distribution of lymphoma subtypes diagnosed at the Department of Pathology, Makerere University College of Health Sciences during this period.
  • OBJECTIVE: To examine the frequency and diagnostic profile of lymphomas diagnosed in Uganda in the HIV/AIDS era.
  • SUBJECTS: One thousand and thirteen patients diagnosed with lymphomas in the period 1980-1989.
  • RESULTS: The most common type of non-Hodgkin lymphoma was Burkitt lymphoma (36%).
  • CONCLUSION: There was a decrease in histopathologically diagnosed lymphomas in Uganda in the period 1980-1989.
  • Burkitt lymphoma continues to be the most common subtype diagnosed, some major lymphoma subtypes like T-cell and follicular lymphomas were not reported in the country in the HIV/AIDS era.
  • [MeSH-major] Disease Outbreaks. HIV Infections / complications. Lymphoma / epidemiology


23. Mahieux R, Gessain A: [New human retroviruses: HTLV-3 and HTLV-4]. Med Trop (Mars); 2005 Nov;65(6):525-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T cell leukemia/lymphoma virus Type 1 and 2 (HTLV-1 and HTLV-2), together with their simian counterparts (STLV-1, STLV-2 and STLV-3), belong to the Primate T lymphotropic viruses group (PTLV).
  • HTLV-1 infects 15 to 20 million people worldwide, while STLV-1 is endemic in a number of simian species living in the Old World.
  • On the opposite, there is no close human homolog of the two STLV-2 strains that have been discovered in African bonobos chimpanzees.
  • They are endemic in several monkey species that live in west, central and east Africa.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555510.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 23
  •  go-up   go-down


24. Lee SJ, Perera L, Coulter SJ, Mohrenweiser HW, Jetten A, Goldstein JA: The discovery of new coding alleles of human CYP26A1 that are potentially defective in the metabolism of all-trans retinoic acid and their assessment in a recombinant cDNA expression system. Pharmacogenet Genomics; 2007 Mar;17(3):169-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: CYP26A1 was sequenced in 24 Caucasians, 24 African-Americans, 24 Asians, and 20 individuals of unknown racial origin. cDNA constructs for wild-type and coding alleles of CYP26A1 were constructed in a pcDNA3.1 expression vector and expressed in Cos-1 cells.
  • A FLAG tag at the C-terminal end of the cDNA was used to quantitate the recombinant CYP26A1 proteins.

  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell. 2000 Jan;5(1):121-31 [10678174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6403-8 [10823918.001]
  • [Cites] Biochem Pharmacol. 2000 Aug 15;60(4):517-26 [10874126.001]
  • [Cites] J Mol Biol. 2000 Sep 8;302(1):205-17 [10964570.001]
  • [Cites] Mol Endocrinol. 2000 Sep;14(9):1483-97 [10976925.001]
  • [Cites] Mol Pharmacol. 2000 Dec;58(6):1341-8 [11093772.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):213-25 [11157777.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):226-40 [11157778.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2001;2:9-39 [11701642.001]
  • [Cites] Nat Genet. 2002 May;31(1):84-8 [11953746.001]
  • [Cites] Nat Genet. 2002 May;31(1):7-8 [11953747.001]
  • [Cites] Am J Hematol. 2002 May;70(1):39-47 [11994980.001]
  • [Cites] Annu Rev Nutr. 2002;22:347-81 [12055350.001]
  • [Cites] Biophys J. 2003 Jan;84(1):57-68 [12524265.001]
  • [Cites] Curr Drug Metab. 2003 Feb;4(1):1-10 [12570742.001]
  • [Cites] Nature. 2003 Jul 24;424(6947):464-8 [12861225.001]
  • [Cites] Pharmacogenetics. 2003 Aug;13(8):461-72 [12893984.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):77-85 [14532297.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9497-503 [14676196.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38091-4 [15258162.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6265-75 [15448016.001]
  • [Cites] Dev Dyn. 1995 Mar;202(3):312-23 [7780180.001]
  • [Cites] FASEB J. 1996 Jul;10(9):940-54 [8801176.001]
  • [Cites] J Biol Chem. 1996 Nov 22;271(47):29922-7 [8939936.001]
  • [Cites] Eur J Pediatr Surg. 1996 Dec;6 Suppl 1:44-5 [9008829.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18538-41 [9228017.001]
  • [Cites] Leuk Lymphoma. 2005 Oct;46(10):1497-506 [16194896.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2006 Feb;76(2):86-95 [16463413.001]
  • [Cites] Mol Pharmacol. 2000 Sep;58(3):483-90 [10953040.001]
  • [Cites] J Bone Joint Surg Am. 1978 Apr;60(3):373-83 [649642.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5597-601 [1829523.001]
  • [Cites] Cell. 1991 Oct 4;67(1):89-104 [1680565.001]
  • [Cites] J Biol Chem. 1993 Oct 15;268(29):21545-52 [8408005.001]
  • [Cites] Nature. 1993 Nov 25;366(6453):340-4 [8247127.001]
  • [Cites] Nucleic Acids Res. 1994 Nov 11;22(22):4673-80 [7984417.001]
  • [Cites] Structure. 1995 Jan 15;3(1):41-62 [7743131.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4163-73 [9250660.001]
  • [Cites] Eur J Biochem. 1997 Jul 15;247(2):625-34 [9266706.001]
  • [Cites] Hum Mutat. 1998;11(1):1-3 [9450896.001]
  • [Cites] Genomics. 1998 Mar 1;48(2):270-2 [9521883.001]
  • [Cites] Genome Res. 1998 Dec;8(12):1229-31 [9872978.001]
  • [Cites] Science. 1999 Oct 15;286(5439):487-91 [10521338.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Apr;313(1):302-9 [15634941.001]
  • [Cites] Mol Pharmacol. 2005 May;67(5):1808-17 [15703382.001]
  • [Cites] Biochem Pharmacol. 2005 Jun 1;69(11):1595-601 [15896339.001]
  • [Cites] Biochem Soc Trans. 2005 Aug;33(Pt 4):747-53 [16042591.001]
  • [Cites] Lancet Oncol. 2005 Sep;6(9):712-20 [16129372.001]
  • (PMID = 17460545.001).
  • [ISSN] 1744-6872
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 ES021024-26; United States / NIEHS NIH HHS / ES / Y1-ES-8054-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Recombinant Proteins; 5688UTC01R / Tretinoin; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / retinoic acid 4-hydroxylase
  • [Other-IDs] NLM/ NIHMS47357; NLM/ PMC2393551
  •  go-up   go-down


25. Pereira CM, Lopes AP, Meneghini AJ, Silva GB, Monteiro MC, Botelho Tde L: Burkitt's lymphoma in a young Brazilian boy. Malays J Pathol; 2010 Jun;32(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in a young Brazilian boy.
  • Burkitt's lymphoma is not an uncommon malignancy in the paediatric population.
  • It is a high-grade non-Hodgkin B-cell lymphoma which may present as endemic, sporadic and human immunodeficiency-associated subtypes.
  • The African, or endemic, variant usually involves the maxilla and other facial bones while head and neck manifestations in sporadic Burkitt's lymphoma are rare.
  • We described a case of oral Burkitt's lymphoma involving the right jaw in a 4-year-old boy.
  • [MeSH-major] Burkitt Lymphoma / pathology. Mandibular Neoplasms / pathology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20614728.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


26. Lin E, Boire A, Hemmige V, Husain AN, Sorrentino M, Nathan S, Akhter SA, Dickstein J, Archer SL: Cardiac tamponade mimicking tuberculous pericarditis as the initial presentation of chronic lymphocytic leukemia in a 58-year-old woman: a case report. J Med Case Rep; 2010;4:246
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is rarely considered in the differential diagnosis of patients presenting with tamponade or a large, bloody pericardial effusion.
  • In patients without known cancer, a large, bloody pericardial effusion raises the possibility of tuberculosis, particularly in patients from endemic areas.
  • CASE PRESENTATION: We report the case of a 58-year-old African American-Nigerian woman with a history of travel to Nigeria and a positive tuberculin skin test who presented with cardiac tamponade.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1979 Oct;67(4):719-23 [495642.001]
  • [Cites] Postgrad Med J. 1989 Oct;65(768):773-5 [2616408.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):322-4 [6574803.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):944-51 [7037154.001]
  • [Cites] Postgrad Med J. 1994 Oct;70(828):703-7 [7831164.001]
  • [Cites] Heart. 1996 Jan;75(1):67-71 [8624876.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):829-32 [17454648.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1168-9 [9426341.001]
  • [Cites] Chest. 1999 Dec;116(6):1564-9 [10593777.001]
  • [Cites] Am J Med. 2001 Oct 15;111(6):504-5 [11690583.001]
  • [Cites] Am J Cardiol. 2005 Jun 1;95(11):1393-4 [15904655.001]
  • [Cites] Acta Trop. 2006 Aug;99(1):67-74 [16950165.001]
  • [Cites] Clin Lab Haematol. 1996 Jun;18(2):117-9 [8866146.001]
  • (PMID = 20684780.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2923171
  •  go-up   go-down


27. Sissolak G, Abayomi EA, Jacobs P: AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART): an African perspective. Transfus Apher Sci; 2007 Aug;37(1):63-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS defining lymphomas in the era of highly active antiretroviral therapy (HAART): an African perspective.
  • The intermediate to high grade B-cell non-Hodgkin lymphomas are now one of three malignant AIDS defining conditions.
  • While co-infection with oncogenic agents including the human herpes 8 or Epstein-Barr virus offer targets in preventive treatment strategies for these AIDS defining lymphomas (ADL), administration of highly active antiretroviral therapy leading to immune reconstitution permits use of standard or even high-dose cytotoxic drug regimens with curative intent.
  • Socio-economic considerations have an impact especially in resource limited settings while availability of tools for appropriate geno-phenotypic diagnosis and immunological monitoring such as the CD4 cell count will play an important role in the risk stratification as well as disease management.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / complications


28. Kanai K, Satoh Y, Saiki Y, Ohtani H, Sairenji T: Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1. Virus Genes; 2007 Jan;34(1):55-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difference of Epstein-Barr virus isolates from Japanese patients and African Burkitt's lymphoma cell lines based on the sequence of latent membrane protein 1.
  • To characterize the genomic relationship between Japanese EBV and the EBV isolates of other countries, we analyzed the LMP1 nucleotide sequences in EBV positive cell lines and clinical specimens, including five African Burkitt's lymphoma (BL) cell lines, a Japanese BL cell line, a B-lymphoblastoid cell line, a nasopharyngeal carcinoma hybrid cell line, six gastric carcinoma tissues, two peripheral blood mononuclear cells, and a B95-8 cell line, which contained the prototype EBV genome.
  • The results indicate that the Japanese EBV isolates are greatly different from the African BL isolates but are closely related to the China 1, which is a strain of Chinese EBV isolates.
  • [MeSH-major] Burkitt Lymphoma / virology. Herpesvirus 4, Human / genetics. Viral Matrix Proteins / genetics

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Dec 15;84(12):4053-60 [7994023.001]
  • [Cites] Blood. 1996 Jul 1;88(1):242-51 [8704180.001]
  • [Cites] Int J Cancer. 1973 Mar 15;11(2):327-37 [4364259.001]
  • [Cites] Oncogene. 1992 Nov;7(11):2131-40 [1331932.001]
  • [Cites] Int J Cancer. 1972 Jul 15;10(1):44-57 [4122458.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9150-4 [8415670.001]
  • [Cites] J Med Virol. 2004 Aug;73(4):583-8 [15221903.001]
  • [Cites] Cell. 1985 Dec;43(3 Pt 2):831-40 [3000618.001]
  • [Cites] J Virol. 2004 Jul;78(13):7131-7 [15194789.001]
  • [Cites] Head Neck. 2004 Jul;26(7):619-24 [15229905.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):191-8 [9422536.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1300-10 [4174339.001]
  • [Cites] Head Neck. 2004 Jul;26(7):573-83 [15229899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11963-8 [9751773.001]
  • [Cites] Arch Otorhinolaryngol. 1984;239(1):87-92 [6318711.001]
  • [Cites] J Biomed Sci. 2003 Sep-Oct;10(5):490-504 [12928589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Jan;70(1):190-4 [4346033.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3491-501 [8896415.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):351-9 [11793387.001]
  • [Cites] Lancet. 1964 Feb 1;1(7327):238-40 [14086209.001]
  • [Cites] J Med Virol. 2003 Feb;69(2):251-7 [12683415.001]
  • [Cites] J Virol. 1967 Oct;1(5):1045-51 [4912237.001]
  • [Cites] Lancet. 1964 Feb 1;1(7327):252-3 [14090852.001]
  • [Cites] Jpn J Cancer Res. 1990 Mar;81(3):272-8 [2161814.001]
  • [Cites] Virology. 1999 Aug 15;261(1):79-95 [10441557.001]
  • [Cites] J Gen Virol. 1994 Oct;75 ( Pt 10):2729-40 [7931159.001]
  • [Cites] J Med Virol. 2002 May;67(1):59-66 [11920819.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):17-23 [8546204.001]
  • [Cites] J Interferon Cytokine Res. 1997 Oct;17(10):597-602 [9355960.001]
  • [Cites] Mutat Res. 2000 Dec 20;457(1-2):69-78 [11106799.001]
  • [Cites] Arch Virol. 2004 Aug;149(8):1515-26 [15290377.001]
  • [Cites] J Clin Pathol. 1965 May;18:261-73 [14304234.001]
  • [Cites] Oncogene. 1996 Oct 3;13(7):1549-53 [8875994.001]
  • [Cites] Virus Genes. 1991 Apr;5(2):147-56 [1647567.001]
  • [Cites] J Med Virol. 1999 Feb;57(2):152-8 [9892400.001]
  • [Cites] Acta Pathol Jpn. 1993 Oct;43(10):574-81 [8291445.001]
  • (PMID = 16917741.001).
  • [ISSN] 0920-8569
  • [Journal-full-title] Virus genes
  • [ISO-abbreviation] Virus Genes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  •  go-up   go-down


29. Rathi S, Shakir F, Sech C, Lazzara R: Non-hodgkin lymphoma causing acute myocardial infarction and tachyarrhythmia. Am J Cardiol; 2009 Aug 1;104(3):450-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-hodgkin lymphoma causing acute myocardial infarction and tachyarrhythmia.
  • [MeSH-major] Heart Neoplasms / secondary. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / pathology. Myocardial Infarction / etiology. Tachycardia / etiology
  • [MeSH-minor] Adult. African Americans. Electrocardiography. Female. Heart Conduction System. Humans. Myocardium. Neoplasm Staging


30. Wilmshurst JM, Burgess J, Hartley P, Eley B: Specific neurologic complications of human immunodeficiency virus type 1 (HIV-1) infection in children. J Child Neurol; 2006 Sep;21(9):788-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric human immunodeficiency virus type 1 (HIV-1) infection is endemic throughout southern Africa.
  • They presented with progressive multifocal leukoencephalopathy, myelopathy, intractable seizures, acute vasculitis and blindness, hemiplegia, peripheral neuropathy, and paraspinal lymphoma.
  • A similar spectrum of neurologic manifestations is likely to occur in other sub-Saharan African countries, characterized by high HIV prevalence.
  • [MeSH-major] Burkitt Lymphoma / complications. Central Nervous System Viral Diseases / diagnosis. Cerebrovascular Disorders / diagnosis. HIV Infections / complications. HIV-1
  • [MeSH-minor] Child. Child Development. Child, Preschool. Female. Humans. Male. South Africa. Spinal Cord Neoplasms / complications. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / virology


31. Koffi GK, Tolo A, Nanho DC, N'dathz E, Kouassi MY, N'Diaye FD, Kouakou B, Meité N, Ayemou R, Sekongo M, Kouehion P, Meité M, Tea ND, Sangaré A, Sanogo I: Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire. Int J Hematol; 2010 Jun;91(5):838-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment with CMA, a low intermediate regimen, in endemic Burkitt lymphomas in sub-Saharian Africa: experience of Côte d'Ivoire.
  • African Burkitt lymphomas (BL) are highly aggressive lymphomas mainly affecting children and young adults in Africa.
  • This lymphoma was marked by its high sensitivity to chemotherapy in comparison to Sporadic Burkitt lymphoma.
  • Eighty-five of the 105 children registered were evaluated for response; there were 46 boys and 39 girls, whose age at diagnosis ranged from 3 to 18 years (median 11 years), admitted to the Hematology National Teaching Hospital of Abidjan in the period 1998-2008 with a diagnosis of BL on histological review and who were given CMA chemotherapy with curative intent are included in this analysis.
  • Fifty-three of patients were alive in first CR at a median survival rate period of 2 years (range 82 days to 9 years) and are continuously disease free from Burkitt lymphomas.
  • Twelve patients relapse after CR and died of lymphoma progression.
  • More than 32 patients died, as a result of lymphoma progression.
  • In conclusion, CMA protocol shows the high sensitivity of African Burkitt lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Methotrexate / therapeutic use

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]
  • [Cites] Tunis Med. 1984 Jan-Feb;62(1):73-7 [6528380.001]
  • [Cites] Eur J Cancer Clin Oncol. 1983 Jun;19(6):741-6 [6683647.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1264-74 [12181251.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):133-8 [1985162.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:258-69 [14448554.001]
  • [Cites] Ann Oncol. 2004 Jul;15(7):1072-8 [15205201.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Clin Oncol. 1986 Dec;4(12):1732-9 [3491184.001]
  • [Cites] Int J Cancer. 1980 Sep 15;26(3):261-6 [7287207.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • (PMID = 20480270.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


32. Chuka-Okosa CM, Uche NJ, Kizor-Akaraiwe NN: Orbito-ocular neoplasms in Enugu, South-Eastern, Nigeria. West Afr J Med; 2008 Jul;27(3):144-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Squamous papilloma and Burkitt's lymphoma each accounting for 9.3% of the tumours in the series were the third most commonly occurring ones.

  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19256317.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


33. Omoti CE, Olu-Eddo AN, Nwannadi AI: Co-existence of TB and adult haematological cancers in Benin City, Nigeria. Trop Doct; 2009 Oct;39(4):205-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 20 cases of haematological cancers co-existing with TB in a tertiary hospital in an African setting between January 2005 and September 2008 were analysed.
  • Lymphoma and leukaemia were the most common malignancies associated with TB.
  • Chemoprophylaxis might be indicated in TB endemic areas.

  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762570.001).
  • [ISSN] 0049-4755
  • [Journal-full-title] Tropical doctor
  • [ISO-abbreviation] Trop Doct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS: Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol; 2007 Dec;139(5):809-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology.
  • The 2001 World Health Organization classification scheme considers B-cell chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in an aggregate category (CLL/SLL) because of shared clinicopathological features.
  • We have estimated age-adjusted incidence rates (IRs) of CLL and SLL in the population-based Surveillance, Epidemiology and End Results Program in the United States to analyse patterns of CLL and SLL separately and jointly.
  • [MeSH-minor] Adult. African Continental Ancestry Group / statistics & numerical data. Age Distribution. Aged. Asian Continental Ancestry Group / statistics & numerical data. European Continental Ancestry Group / statistics & numerical data. Female. Humans. Incidence. Male. Middle Aged. SEER Program. Sex Distribution. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941952.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  •  go-up   go-down


35. Berrios-Rivera JP, Fang S, Cabanillas ME, Cabanillas F, Lu H, Du XL: Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol; 2007 Apr;30(2):163-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma.
  • OBJECTIVE: The objective of this study was to determine the variations in the use of chemotherapy and radiation therapy in a large nationwide and population-based cohort of older patients with non-Hodgkin lymphoma (NHL).
  • METHODS: We studied a retrospective cohort of 13,570 patients diagnosed with incident NHL at age > or =65 in 1992 through 1999 identified from the Surveillance, Epidemiology and End Results-Medicare-linked database.
  • RESULTS: Of 13,570 patients with NHL, 52% received chemotherapy within 6 months of diagnosis.
  • In multivariate analysis, there was no significant association between the receipt of chemotherapy and gender or year of diagnosis, but blacks had statistically significant lower odds of receiving chemotherapy than white patients (odds ratio = 0.66, 95% confidence interval: 0.55-0.80).
  • The percentages of patients receiving radiation therapy, chemotherapy, or both were 11%, 39%, and 13%, respectively; 37% of patients with NHL did not receive any of these treatments within 6 months of diagnosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] African Continental Ancestry Group. Aged. Aged, 80 and over. Cohort Studies. Combined Modality Therapy. European Continental Ancestry Group. Female. Geography. Humans. Male. Medicare. Neoplasm Staging. Registries. Retrospective Studies. United States

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414466.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


36. Yamamoto JF, Goodman MT: Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control; 2008 May;19(4):379-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • African-Americans had the highest rates of HTLV-1 positive adult T-cell leukemia/lymphoma.
  • [MeSH-minor] African Americans / ethnology. Age Factors. Asian Americans / ethnology. Female. Hispanic Americans / ethnology. Humans. Incidence. Male. Registries / statistics & numerical data. Risk Factors. Sex Factors. United States / epidemiology

  • Genetics Home Reference. consumer health - acute promyelocytic leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064533.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  •  go-up   go-down


37. Ozumba BC, Nzegwu MA, Anyikam A, Okoye I, Okafor OC: Breast disease in children and adolescents in eastern Nigeria--a five-year study. J Pediatr Adolesc Gynecol; 2009 Jun;22(3):169-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The three cases of malignancy observed included invasive intraductal carcinoma, a non-hodgkin lymphoma, and metastases involving the lymph nodes from an uncharacterized secondary malignancy.
  • [MeSH-major] African Continental Ancestry Group / statistics & numerical data. Breast Diseases / ethnology. Breast Diseases / pathology

  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539203.001).
  • [ISSN] 1873-4332
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Polder K, Wang C, Duvic M, Diwan AH, Parks D, Jankov A, Walker PL, Tong AT, Bull J, Dang NH: Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Leuk Lymphoma; 2005 Dec;46(12):1807-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma.
  • Denileukin diftitox (DAB(389)IL-2 or Ontak) is a synthetic fusion protein with demonstrated efficacy in a number of lymphoproliferative disorders, including non-Hodgkin's lymphoma.
  • We report the case of a 45-year-old man with progressive follicular large cell lymphoma following an autologous stem cell transplant treated with denileukin diftitox who developed a fatal skin rash associated with extensive erythema, edema and large bullae involving his entire body.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Diphtheria Toxin / adverse effects. Interleukin-2 / adverse effects. Lymphoma, Follicular / drug therapy. Stevens-Johnson Syndrome / pathology
  • [MeSH-minor] African Continental Ancestry Group. Dermatitis / pathology. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Fusion Proteins / adverse effects. Texas

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16263585.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox
  •  go-up   go-down


39. Erber E, Lim U, Maskarinec G, Kolonel LN: Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort. Int J Cancer; 2009 Sep 15;125(6):1440-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort.
  • Severe immune dysfunction is an established risk factor of lymphoma, but the role of moderate alterations of immunity is not clear and prospective investigations are needed.
  • We examined several immune-related disorders and medications in relation to non-Hodgkin lymphoma (NHL) in the Multiethnic Cohort.
  • Over 215,000 subjects of African American, Caucasian, Japanese American, Latino and Native Hawaiian ancestry aged 45-75 years completed a questionnaire, including information on medical history, in 1993-1996.
  • Participants with a history of blood transfusion were at increased risk with HR = 1.39 (95% CI: 1.06-1.84) in men and HR = 1.22 (95% CI: 0.94-1.58) in women, especially for the diffuse large B-cell lymphoma subtype.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2069-77 [17119030.001]
  • [Cites] Arch Intern Med. 2005 Nov 14;165(20):2337-44 [16287762.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Cancer Detect Prev. 2006;30(1):99-101 [16495019.001]
  • [Cites] Acta Oncol. 2006;45(3):258-71 [16644568.001]
  • [Cites] Am J Epidemiol. 2006 Sep 1;164(5):497-504 [16840523.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Cancer Causes Control. 2007 Oct;18(8):821-31 [17588155.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):196-203 [18187389.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):163-73 [18038187.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] Clin Trials. 2008;5(3):240-7 [18559413.001]
  • [Cites] Int J Cancer. 2008 Aug 15;123(4):888-94 [18506687.001]
  • [Cites] Am J Epidemiol. 2008 Sep 1;168(5):471-80 [18611954.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1155-63 [11700263.001]
  • [Cites] Hepatology. 2002 Apr;35(4):974-6 [11915049.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):401-7 [11927501.001]
  • [Cites] Am J Epidemiol. 2002 Apr 15;155(8):725-31 [11943690.001]
  • [Cites] Transpl Immunol. 2002 Aug;10(2-3):183-90 [12216948.001]
  • [Cites] Cancer Causes Control. 2002 Dec;13(10):965-74 [12588093.001]
  • [Cites] J Obstet Gynaecol Res. 2003 Apr;29(2):96-103 [12755530.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):784-8 [12866040.001]
  • [Cites] J Nutr. 2004 Jan;134(1):205-10 [14704320.001]
  • [Cites] Cancer Causes Control. 2004 May;15(4):419-28 [15141141.001]
  • [Cites] Am J Epidemiol. 2004 Aug 15;160(4):325-30 [15286017.001]
  • [Cites] Cancer. 1971 Jan;27(1):93-9 [5539630.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5510s-5515s [1394165.001]
  • [Cites] Diabetes Res Clin Pract. 1994 Oct;24 Suppl:S43-52 [7859632.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jul 1;15(3):211-22 [9257656.001]
  • [Cites] Ann Intern Med. 1997 Sep 15;127(6):423-8 [9312998.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):237-9 [9935205.001]
  • [Cites] Eur J Surg Suppl. 1998;(582):65-70 [10029368.001]
  • [Cites] Int J Hematol. 1999 Feb;69(2):75-80 [10071454.001]
  • [Cites] BMC Public Health. 2004 Nov 4;4:51 [15527506.001]
  • [Cites] Stat Med. 2004 Dec 30;23(24):3803-20 [15580597.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 20;97(8):587-94 [15840881.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):301-8 [15947882.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] Allergy. 2005 Sep;60(9):1095-7 [16076291.001]
  • [Cites] Allergy. 2005 Sep;60(9):1098-111 [16076292.001]
  • [Cites] Am J Epidemiol. 2005 Nov 15;162(10):965-74 [16192343.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):158-66 [17227999.001]
  • (PMID = 19444913.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35137; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CA / R37 CA054281-17; United States / NCI NIH HHS / CA / R37CA54281; United States / NCI NIH HHS / CA / CA054281-17; United States / NCI NIH HHS / CA / R37 CA054281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine Antagonists
  • [Other-IDs] NLM/ NIHMS137658; NLM/ PMC2734966
  •  go-up   go-down


40. Olowu WA, Elusiyan JB, Badejo SA, Adenowo OA: Acute renal failure in African children with Burkitt's lymphoma: a comparison of two treatment regimens. Pediatr Blood Cancer; 2006 Apr;46(4):446-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute renal failure in African children with Burkitt's lymphoma: a comparison of two treatment regimens.
  • BACKGROUND: The outcome for patients presenting with acute renal failure and Burkitt lymphoma (BLARF) without dialysis is poor.
  • [MeSH-major] Acute Kidney Injury / complications. Acute Kidney Injury / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / complications. Burkitt Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206217.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Pereira NL, Aksoy P, Moon I, Peng Y, Redfield MM, Burnett JC Jr, Wieben ED, Yee VC, Weinshilboum RM: Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol; 2010 Nov;49(5):864-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA samples from 96 European-American, 96 African-American, and 96 Han Chinese-American healthy subjects were used to resequence MME.

  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Oncogene. 2006 Mar 13;25(11):1629-38 [16550163.001]
  • [Cites] J Comput Chem. 2005 Dec;26(16):1701-18 [16211538.001]
  • [Cites] Eur Heart J. 2007 Aug;28(15):1894-903 [17507367.001]
  • [Cites] JAMA. 2008 Jan 23;299(3):296-307 [18212314.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):695-701 [18509313.001]
  • [Cites] Mol Genet Metab. 2008 Jul;94(3):326-35 [18457970.001]
  • [Cites] Hum Mol Genet. 2008 Oct 15;17(R2):R174-9 [18852207.001]
  • [Cites] Pharmacogenet Genomics. 2009 Aug;19(8):567-76 [19623099.001]
  • [Cites] Leuk Lymphoma. 2010 Jul;51(7):1315-25 [20470215.001]
  • [Cites] Nature. 2010 Jul 8;466(7303):243-7 [20555325.001]
  • [Cites] Circulation. 2002 Jan 22;105(3):286-9 [11804980.001]
  • [Cites] Life Sci. 2002 Oct 25;71(23):2701-12 [12383878.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):749-51 [12754344.001]
  • [Cites] Stroke. 2004 Apr;35(4):814-8 [15017020.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1252-9 [15464186.001]
  • [Cites] Anal Biochem. 1984 Aug 15;141(1):62-9 [6388410.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(18):7103-7 [2528730.001]
  • [Cites] Genetics. 1989 Nov;123(3):585-95 [2513255.001]
  • [Cites] J Biol Chem. 1992 Oct 25;267(30):21303-6 [1400441.001]
  • [Cites] Am J Hum Genet. 1995 Mar;56(3):799-810 [7887436.001]
  • [Cites] J Mol Biol. 2000 Feb 18;296(2):341-9 [10669592.001]
  • [Cites] N Engl J Med. 2000 Jul 27;343(4):246-53 [10911006.001]
  • [Cites] Psychiatr Genet. 2000 Jun;10(2):91-4 [10994648.001]
  • [Cites] J Am Coll Cardiol. 2001 Feb;37(2):379-85 [11216950.001]
  • [Cites] Bioessays. 2001 Mar;23(3):261-9 [11223883.001]
  • [Cites] Science. 2001 May 25;292(5521):1552-5 [11375494.001]
  • [Cites] Circulation. 2001 Oct 9;104(15):1856-62 [11591626.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Clin Sci (Lond). 1997 Mar;92(3):255-60 [9093005.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 2):H2372-9 [9374774.001]
  • [Cites] Pathol Biol (Paris). 1998 Mar;46(3):191-200 [9769915.001]
  • [Cites] J Hypertens. 1999 Sep;17(9):1301-5 [10489108.001]
  • [Cites] Curr Probl Cardiol. 2004 Dec;29(12):707-69 [15550914.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32 [15572765.001]
  • [Cites] Cardiovasc Drugs Ther. 2007 Feb;21(1):55-62 [17340039.001]
  • (PMID = 20692264.001).
  • [ISSN] 1095-8584
  • [Journal-full-title] Journal of molecular and cellular cardiology
  • [ISO-abbreviation] J. Mol. Cell. Cardiol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / U19 GM061388; United States / NIGMS NIH HHS / GM / U01 GM61388; United States / NIGMS NIH HHS / GM / R01 GM028157; United States / NHLBI NIH HHS / HL / U10 HL084904; United States / NIGMS NIH HHS / GM / U01 GM061388; United States / NCI NIH HHS / CA / R01 CA132780; United States / NIGMS NIH HHS / GM / R01 GM28157; United States / NHLBI NIH HHS / HL / U01 HL084904; United States / NHLBI NIH HHS / HL / HL 84904; United States / NCRR NIH HHS / RR / UL1 RR024150; United States / NCRR NIH HHS / RR / UL1RR24150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Molecular Chaperones; 85637-73-6 / Atrial Natriuretic Factor; EC 3.4.24.11 / Neprilysin; EC 3.4.25.1 / Proteasome Endopeptidase Complex; HG18B9YRS7 / Valine
  • [Other-IDs] NLM/ NIHMS288622; NLM/ PMC3092155
  •  go-up   go-down


42. Etenna SL, Caron M, Besson G, Makuwa M, Gessain A, Mahé A, Kazanji M: New insights into prevalence, genetic diversity, and proviral load of human T-cell leukemia virus types 1 and 2 in pregnant women in Gabon in equatorial central Africa. J Clin Microbiol; 2008 Nov;46(11):3607-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human T-cell leukemia virus type 1 (HTLV-1) is highly endemic in areas of central Africa; mother-to-child transmission and sexual transmission are considered to be the predominant routes.
  • Sequencing of HTLV-1 env and long terminal repeat fragments showed that all but one strain belonged to the central African subtype B; the outlier was of cosmopolitan subtype A.
  • [MeSH-major] Genetic Variation. HTLV-II Infections / epidemiology. Human T-lymphotropic virus 1 / classification. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 2 / classification. Human T-lymphotropic virus 2 / genetics. Leukemia-Lymphoma, Adult T-Cell / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1993 Jan 2;53(1):48-50 [8416204.001]
  • [Cites] Mol Biol Evol. 1987 Jul;4(4):406-25 [3447015.001]
  • [Cites] Bull Soc Pathol Exot. 1993;86(1):12-5 [8099298.001]
  • [Cites] AIDS Res Hum Retroviruses. 1994 Jun;10(6):753-5 [7915531.001]
  • [Cites] Int J Epidemiol. 1994 Aug;23(4):812-7 [8002196.001]
  • [Cites] Bull Soc Pathol Exot. 1994;87(4):217-21 [7866037.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):4041-5 [7732027.001]
  • [Cites] J Infect Dis. 1995 Jun;171(6):1455-60 [7769278.001]
  • [Cites] J Virol. 1995 Nov;69(11):6980-93 [7474117.001]
  • [Cites] Leukemia. 1995 Dec;9(12):2087-92 [8609721.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):187-92 [8680891.001]
  • [Cites] Med Trop (Mars). 1996;56(1):66-8 [8767797.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 May 1;12(7):635-40 [8743089.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S20-5 [8797699.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S132-45 [8797716.001]
  • [Cites] J Med Virol. 1996 Jan;48(1):22-32 [8825706.001]
  • [Cites] J Virol. 1997 Feb;71(2):1317-33 [8995656.001]
  • [Cites] Neurology. 1997 Feb;48(2):315-20 [9040713.001]
  • [Cites] J Infect Dis. 1997 Aug;176(2):505-9 [9237719.001]
  • [Cites] Virology. 1998 Mar 15;242(2):425-34 [9514966.001]
  • [Cites] J Mol Evol. 1998 May;46(5):602-11 [9545470.001]
  • [Cites] West Indian Med J. 1998 Mar;47(1):23-5 [9619092.001]
  • [Cites] J Virol. 1998 Dec;72(12):10316-22 [9811783.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):430-2 [9833756.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):407-17 [10195750.001]
  • [Cites] Genome Res. 1999 Jun;9(6):525-40 [10400920.001]
  • [Cites] Int J Cancer. 1999 Sep 9;82(6):832-6 [10446450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):7994-9 [15911757.001]
  • [Cites] Retrovirology. 2005;2:30 [15882466.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Am J Trop Med Hyg. 2005 Sep;73(3):560-5 [16172481.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1609-19 [16314474.001]
  • [Cites] Infect Genet Evol. 2007 Jun;7(3):374-81 [16931175.001]
  • [Cites] J Infect Dis. 2007 Aug 15;196(4):510-21 [17624835.001]
  • [Cites] Brief Bioinform. 2008 Jul;9(4):299-306 [18417537.001]
  • [Cites] Int J Cancer. 1988 Nov 15;42(5):687-9 [3182104.001]
  • [Cites] Oncogene. 2000 Oct 12;19(43):4954-60 [11042682.001]
  • [Cites] Mol Biol Evol. 2001 Apr;18(4):661-71 [11264418.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 Apr 10;17(6):563-8 [11350670.001]
  • [Cites] Clin Infect Dis. 2002 Jun 15;34(12):1551-7 [12032888.001]
  • [Cites] Cad Saude Publica. 2003 Sep-Oct;19(5):1227-40 [14666205.001]
  • [Cites] J Gen Virol. 2004 Jan;85(Pt 1):25-9 [14718616.001]
  • [Cites] Am J Trop Med Hyg. 2004 Feb;70(2):158-63 [14993627.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):2020-6 [15131164.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):958-65 [15149509.001]
  • [Cites] J Infect Dis. 2004 Oct 1;190(7):1275-8 [15346338.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Ann Intern Med. 1989 Oct 1;111(7):555-60 [2789009.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1184-7 [2572904.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1226 [2572942.001]
  • [Cites] Lancet. 1990 Dec 1;336(8727):1345-7 [1978165.001]
  • [Cites] J Infect Dis. 1991 Mar;163(3):435-40 [1995717.001]
  • [Cites] J Acquir Immune Defic Syndr. 1991;4(5):468-70 [2016684.001]
  • [Cites] Int J Cancer. 1991 Sep 30;49(3):373-6 [1917135.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):645-6 [1347339.001]
  • [Cites] Lancet. 1992 May 2;339(8801):1110 [1349119.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Int J Epidemiol. 1992 Oct;21(5):989-94 [1468864.001]
  • (PMID = 18845819.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU444083/ EU444084/ EU444085/ EU444086/ EU444087/ EU444088/ EU444089/ EU444090/ EU444091/ EU444092/ EU444093/ EU444094/ EU444095/ EU444096/ EU444097/ EU444098/ EU444099/ EU444100/ EU444101/ EU444102/ EU444103/ EU444104/ EU444105/ EU444106/ EU444107/ EU444108/ EU444109/ EU444110/ EU444111/ EU444112/ EU444113/ EU444114/ EU444115/ EU444116/ EU444117/ EU444118
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2576568
  •  go-up   go-down


43. Sow M, Nkégoum B, Oyono JL, Garoua, Nzokou A: [Epidemiological and histological features of urogenital tumours in Cameroon]. Prog Urol; 2006 Feb;16(1):36-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 2,371 urogenital tumours were identified, corresponding to 520 prostatic adenocarcinomas, 1,066 cases of benign prostatic hyperplasia, 41 testicular tumours (9 seminomatous tumours, 7 non-seminomatous tumours, 18 lymphomas, 4 benign papillomas and 2 rhabdomyosarcomas of the spermatic cord), 169 bladder tumours (25 transitional cell carcinomas, 70 squamous cell carcinomas, 67 adenocarcinomas, 2 lymphomas, 1 sarcoma and 1 benign papilloma), and 136 kidney tumours (20 Wilms tumours, 87 renal cell carcinomas, 6 transitional cell carcinomas, 16 lymphomas, 2 other malignant tumours and 5 adenomas).
  • The urogenital tract can also be the site of endemic Burkitt lymphoma in this country.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16526537.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


44. Tang W, Harmon P, Gulley ML, Mwansambo C, Kazembe PN, Martinson F, Wokocha C, Kenney SC, Hoffman I, Sigel C, Maygarden S, Hoffman M, Shores C: Viral response to chemotherapy in endemic burkitt lymphoma. Clin Cancer Res; 2010 Apr 1;16(7):2055-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Viral response to chemotherapy in endemic burkitt lymphoma.
  • We studied whether cyclophosphamide chemotherapy induces EBV to switch from latent to lytic phases of infection in a series of EBV-associated Burkitt lymphomas.
  • EXPERIMENTAL DESIGN: Children with first presentation of an expanding, solid maxillary or mandibular mass consistent with Burkitt lymphoma underwent fine-needle aspiration just prior to the initiation of cyclophosphamide therapy and again 1 to 5 days later.
  • RESULTS: Among 21 lymphomas expressing EBER prior to chemotherapy, 9 of 10 still expressed EBER on day 1 after therapy whereas only 2 of 11 (18%) specimens still expressed EBER at days 3 to 5, implying that chemotherapy was fairly effective at eliminating latently infected cells.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] J Virol. 2000 Nov;74(21):10223-8 [11024153.001]
  • [Cites] Haematologica. 2009 Nov;94(11):1618-22 [19608677.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jul;45(7):2082-91 [11408227.001]
  • [Cites] Transplantation. 2002 Jan 27;73(2):271-9 [11821743.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1920-6 [11912175.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):23-5 [12426682.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Jan;45(1):1-36 [12482570.001]
  • [Cites] Med Sci Monit. 2003 Jan;9(1):HY1-9 [12552250.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):965-71 [12615710.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):697-702, v-vi [12852651.001]
  • [Cites] J Virol. 2004 Feb;78(4):1893-902 [14747554.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1373-81 [15007085.001]
  • [Cites] Eur J Biochem. 2004 May;271(10):1895-905 [15128299.001]
  • [Cites] Diagn Mol Pathol. 2004 Jun;13(2):61-8 [15167006.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3053-60 [15284255.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):378-85 [15507678.001]
  • [Cites] EMBO J. 1986 Oct;5(10):2599-607 [3023050.001]
  • [Cites] Cancer Res. 1989 Jan 1;49(1):1-7 [2491747.001]
  • [Cites] J Virol. 1989 Apr;63(4):1729-36 [2538653.001]
  • [Cites] J Virol. 1989 Jul;63(7):3109-16 [2542618.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6550-4 [1713681.001]
  • [Cites] Semin Cancer Biol. 1992 Oct;3(5):285-95 [1335792.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):969-72 [8640787.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9194-9 [8799177.001]
  • [Cites] Semin Cancer Biol. 1996 Aug;7(4):217-26 [8946606.001]
  • [Cites] Hum Gene Ther. 1998 May 20;9(8):1131-41 [9625252.001]
  • [Cites] J Virol. 1998 Oct;72(10):7978-84 [9733836.001]
  • [Cites] J Virol. 1998 Nov;72(11):9323-8 [9765483.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):6-11 [10077144.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1485-91 [10197618.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:258-69 [14448554.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1691-702 [15547182.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):519-27 [15696119.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):33871-80 [16956891.001]
  • [Cites] J Virol. 2007 Jan;81(2):1037-42 [17079287.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2571-8 [17119113.001]
  • [Cites] Adv Cancer Res. 2007;97:81-109 [17419942.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:277-84 [18024641.001]
  • [Cites] J Virol Methods. 2008 Jan;147(1):26-36 [17870188.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):705-9 [18258198.001]
  • [Cites] Trop Doct. 2008 Jan;38(1):7-11 [18302850.001]
  • [Cites] J Virol. 2008 May;82(10):4706-19 [18337569.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):279-92 [18556771.001]
  • [Cites] Med Oncol. 2009;26(1):1-9 [18461290.001]
  • [Cites] Cancer Biol Ther. 2009 Jun;8(11):987-95 [19448399.001]
  • [Cites] J Virol. 2009 Oct;83(20):10694-709 [19656890.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5781-8 [11059774.001]
  • (PMID = 20233888.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA066519; United States / NCI NIH HHS / CA / R01 CA058853; United States / NCI NIH HHS / CA / CA066519-16; United States / NCI NIH HHS / CA / R01-CA66519; United States / NCI NIH HHS / CA / R01 CA066519-16
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Viral; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS179000; NLM/ PMC2848899
  •  go-up   go-down


45. Smith JM, Rudser K, Gillen D, Kestenbaum B, Seliger S, Weiss N, McDonald RA, Davis CL, Stehmen-Breen C: Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation; 2006 Jan 27;81(2):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System.
  • BACKGROUND: Characterization of the incidence of posttransplant lymphoma over time may help guide the timing and intensity of posttransplant monitoring.
  • We analyzed the United States Renal Data System to describe the occurrence of lymphoma following renal transplantation.
  • METHODS: All end-stage renal disease patients placed on the transplant waiting list between January 1, 1990 and December 31, 1999 were considered.
  • Survival analysis was used to estimate lymphoma risk in renal transplant patients.
  • RESULTS: Of 89,260 eligible patients, a total of 556 lymphoma cases were identified with 357 in transplant patients.
  • The overall rate of posttransplant lymphoma was 33.3/10,000 person-years in transplant patients.
  • There was variation in the duration and magnitude of increased lymphoma risk by age.
  • The highest rates of lymphoma were among transplanted patients in the first 12 months, after which the rate of lymphoma decreased.
  • Among Caucasian transplant recipients less than 25 years of age, the adjusted relative risk of lymphoma ranged from 13.82 [95% CI: (3.96, 48.15)] within 6 months posttransplant to 3.46 [95% CI: (0.69, 17.44)] within months 30-36 posttransplant.
  • The risk of lymphoma differed by race, with Caucasian patients at nearly double the risk of African-Americans.
  • Gender was not associated with lymphoma incidence.
  • CONCLUSIONS: We found and quantified a time-varying relationship between renal transplant and lymphoma risk.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma / etiology


46. Lemerle J, Barsaoui S, Harif M, Hireche K, Ladjadj Y, Moreira C, Andoh J, Doumbé P, Togo B, Kam L, Rafaramino F, Patte C, Tournade MF, Raphaël M, Boccon-Gibod L, Mallon B, Raquin MA, Msefer Alaoui F: [Treatment of childhood cancer in Africa. Action of the Franco-African childhood cancer group]. Med Trop (Mars); 2007 Oct;67(5):497-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of childhood cancer in Africa. Action of the Franco-African childhood cancer group].
  • [Transliterated title] Le traitement des cancers de l'enfant en Afrique. Travaux du groupe franco-africain d'oncologie pédiatrique.
  • The Franco-African Childhood Cancer Group (French acronym, GFAOP) was founded in 2000 with aim of reducing this unfavorable situation in Africa.
  • The first feasibility trials were carried out on nephroblastoma and Burkitt's lymphoma in 12 pilot units in North Africa, West Africa, and Madagascar.
  • In the first study from 2001 to 2005 we treated 306 cases of Burkitt's lymphoma using French LMB protocols adapted to the African setting and achieved a survival rate of 61%.
  • Altogether from 2001 to 2007 more than 1000 cases of nephroblastoma and Burkitt's lymphoma were treated in African hospitals by African doctors and nurses.
  • African and French doctors worked together on protocol design, trial management, and data analysis.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225736.001).
  • [ISSN] 0025-682X
  • [Journal-full-title] Médecine tropicale : revue du Corps de santé colonial
  • [ISO-abbreviation] Med Trop (Mars)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


47. Lee NJ, Fermo JD: Warfarin and royal jelly interaction. Pharmacotherapy; 2006 Apr;26(4):583-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 87-year-old African-American man came to the internal medicine clinic for a routine anticoagulation management visit.
  • His medical history was significant for stage IV-A follicular non-Hodgkin's lymphoma, atrial fibrillation, and hypertension.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. WARFARIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16553520.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Fatty Acids; 0 / Insect Hormones; 5Q7ZVV76EI / Warfarin; 8031-67-2 / royal jelly
  •  go-up   go-down


48. Erber E, Maskarinec G, Gill JK, Park SY, Kolonel LN: Dietary patterns and the risk of non-Hodgkin lymphoma: the Multiethnic Cohort. Leuk Lymphoma; 2009 Aug;50(8):1269-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary patterns and the risk of non-Hodgkin lymphoma: the Multiethnic Cohort.
  • We examined dietary patterns and the risk of non-Hodgkin lymphoma (NHL) in the Multiethnic Cohort, which includes more than 215,000 Caucasians, African-Americans, Japanese-Americans, Native Hawaiians, and Latinos aged 45-75 at baseline.
  • However, the Vegetables pattern was inversely related to risk in Caucasian women with a hazard ratio of 0.56 (P(trend) = 0.04), and the Fat and Meat pattern was associated with a fivefold higher risk of follicular lymphoma in men (P(trend) = 0.03).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Food Chem Toxicol. 1999 Sep-Oct;37(9-10):943-8 [10541449.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):477-85 [10815692.001]
  • [Cites] Am J Clin Nutr. 2001 Jan;73(1):1-2 [11124739.001]
  • [Cites] Nutrition. 2001 Jul-Aug;17(7-8):669-73 [11448594.001]
  • [Cites] Curr Opin Lipidol. 2002 Feb;13(1):3-9 [11790957.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3 Suppl):508S-513S [12936941.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):454-66 [14977641.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1665-76 [15466985.001]
  • [Cites] Fed Proc. 1975 Feb;34(2):197-201 [1116615.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5492s-5495s [1394161.001]
  • [Cites] Am J Med. 1994 Sep 26;97(3A):5S-13S; discussion 22S-28S [8085584.001]
  • [Cites] Am J Clin Nutr. 1995 Dec;62(6 Suppl):1462S-1476S [7495247.001]
  • [Cites] J Am Diet Assoc. 1996 Oct;96(10):1027-39 [8841165.001]
  • [Cites] Nutr Cancer. 1997;27(3):256-60 [9101555.001]
  • [Cites] Leuk Res. 1998 May;22(5):445-52 [9652731.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):512-20 [15734980.001]
  • [Cites] J Nutr. 2005 Apr;135(4):843-9 [15795445.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):469-76 [15992695.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2871-6 [16385566.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1401-10 [16762953.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2477-87 [17169793.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):358-70 [10695594.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):392-5 [17337642.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] J Postgrad Med. 2007 Apr-Jun;53(2):139-43 [17495384.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):603-10 [17220476.001]
  • [CommentIn] Leuk Lymphoma. 2009 Aug;50(8):1237-8 [19811328.001]
  • (PMID = 19811330.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA090956-05; United States / NCI NIH HHS / CA / R25 CA090956; United States / NCI NIH HHS / PC / N01-PC-35137; United States / NCI NIH HHS / PC / N01 PC035137; United States / NCI NIH HHS / CA / N01PC35137; United States / NCI NIH HHS / CA / R25 CA 90956; None / None / / N01 PC035137; United States / NCI NIH HHS / CA / R37 CA54281; United States / NCI NIH HHS / CA / CA090956-05; United States / NCI NIH HHS / CA / R37 CA054281-16; United States / NCI NIH HHS / CA / R37 CA054281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats
  • [Other-IDs] NLM/ NIHMS215717; NLM/ PMC2903438
  •  go-up   go-down


49. Mbulaiteye SM, Talisuna AO, Ogwang MD, McKenzie FE, Ziegler JL, Parkin DM: African Burkitt's lymphoma: could collaboration with HIV-1 and malaria programmes reduce the high mortality rate? Lancet; 2010 May 8;375(9726):1661-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] African Burkitt's lymphoma: could collaboration with HIV-1 and malaria programmes reduce the high mortality rate?
  • [MeSH-major] Burkitt Lymphoma / mortality. Government Programs. HIV Infections / therapy. HIV-1. International Cooperation. Malaria, Falciparum / therapy


50. Tolo-Diebkilé A, Koffi GK, Nanho CD, Sawadogo D, Kouakou B, Siransi-Bogui L, Ayémou R, Sanogo I: [Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan]. Bull Cancer; 2010 May;97(5):507-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of the protocol CMA reinforced in the treatment of endemic Burkitt lymphoma at CHU of Yopougon in Abidjan].
  • [Transliterated title] Evaluation du protocole CMA renforcé dans le traitement du lymphome de Burkitt endémique au CHU de Yopougon à Abidjan.
  • We report the results of the protocol CMA (cyclophosphamide, methotrexate, Aracytine) reinforced of 26 patients affected by Burkitt lymphoma in facial-maxillary localisation, in a retrospective study from January 2000 till December 2007 and prospective from January till September 2008.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Facial Neoplasms / drug therapy. Maxillary Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20071300.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


51. Akhiwu WO, Igbe AP, Aligbe JU, Eze GI, Akang EE: Malignant childhood solid tumours in Benin City, Nigeria. West Afr J Med; 2009 Jul-Aug;28(4):222-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological types, in descending order of frequency, were lymphoma 28(33.3%), nephroblastoma 18 (21.4%), retinoblastoma, rhabdomyosarcoma 12 (14.3%) each, and carcinoma 9 (10.7%).
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / pathology. Hospitals, Teaching / statistics & numerical data. Humans. Infant. Infant, Newborn. Kidney Neoplasms / epidemiology. Kidney Neoplasms / pathology. Lymphoma / epidemiology. Lymphoma / pathology. Male. Nigeria / epidemiology. Retinal Neoplasms / epidemiology. Retinal Neoplasms / pathology. Retinoblastoma / epidemiology. Retinoblastoma / pathology. Rhabdomyosarcoma / epidemiology. Rhabdomyosarcoma / pathology. Risk Factors. Wilms Tumor / epidemiology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425736.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


52. Magrath I: Lessons from clinical trials in African Burkitt lymphoma. Curr Opin Oncol; 2009 Sep;21(5):462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lessons from clinical trials in African Burkitt lymphoma.
  • The present review focuses on the treatment of an AIDS-defining malignancy, Burkitt lymphoma, since the discovery of the tumor in 1958 to provide a backdrop to the increasing necessity of dealing with AIDS-associated Burkitt lymphoma in Africa.
  • RECENT FINDINGS: In Africa, it appears that AIDS-associated Burkitt lymphoma is increasing, but although treatment outcome is presently poor, the demonstration that highly active antiretroviral therapy permits the same treatment results to those in AIDS-unassociated Burkitt lymphoma provides hope for the future.
  • SUMMARY: In the 1960s, the extraordinary response of Burkitt lymphoma to chemotherapy provided considerable encouragement to pioneer oncologists.
  • The impact of the HIV epidemic on the epidemiology and treatment of African Burkitt lymphoma will receive increasing focus in the coming years.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620863.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


53. Feller L, White JP, Bouckaert M, Muthuphei MN: Diffuse infiltrative CD8+ lymphocytosis syndrome: review of the literature and report of a case. SADJ; 2007 Aug;62(7):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Parotid enlargement in HIV-seropositive subjects may represent HIV-associated lymphoepithelial lesions, hyperplastic lymphadenopathy, lymphoma, bacterial and viral infections, Sjögren's syndrome and DILS.
  • Therefore confirmatory histopathological diagnosis and immunohistochemical analysis following a biopsy is essential to determine the exact nature of the salivary gland enlargement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019812.001).
  • [ISSN] 1029-4864
  • [Journal-full-title] SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging
  • [ISO-abbreviation] SADJ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] South Africa
  • [Number-of-references] 32
  •  go-up   go-down


54. Yu JB, Blitzblau RC, Decker RH, Housman DM, Wilson LD: Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. J Clin Oncol; 2008 Mar 20;26(9):1483-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database.
  • PURPOSE: Primary CD30+ cutaneous lymphoproliferative disease (PCLPD) is a spectrum of indolent cutaneous T-cell lymphomas.
  • The primary intention of the analysis of the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database was to report epidemiologic information and overall survival of patients with PCLPD.
  • Median age at diagnosis was 61 years (range, 5 to 98 years).
  • [MeSH-major] Antigens, CD30 / analysis. Biomarkers, Tumor / analysis. Lymphoma, T-Cell, Cutaneous / mortality
  • [MeSH-minor] Adolescent. Adult. African Americans / statistics & numerical data. Aged. Aged, 80 and over. Analysis of Variance. Asian Americans / statistics & numerical data. Child. Child, Preschool. European Continental Ancestry Group / statistics & numerical data. Female. Head and Neck Neoplasms / mortality. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. SEER Program. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2008 May 1;26(13):2238
  • (PMID = 18349400.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor
  •  go-up   go-down


55. Ozgönenel B, Savaşan S, Rabah R, Mohamed AN, Cushing B: Pediatric EBV-positive T-cell/histiocyte-rich large B-cell lymphoma with clonal cells in the bone marrow without overt involvement. Leuk Lymphoma; 2005 Mar;46(3):465-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric EBV-positive T-cell/histiocyte-rich large B-cell lymphoma with clonal cells in the bone marrow without overt involvement.
  • T-cell/histiocyte-rich large B-cell lymphoma (TCHRLBCL) is a variant of large B-cell lymphoma only rarely encountered in children.
  • Here we report the case of an 8-year-old African American boy with Epstein-Barr virus (EBV)-positive TCHRLBCL who initially presented with right submandibular, anterior cervical and supraclavicular lymphadenopathy.
  • The patient remains in remission 26 months after the initial diagnosis.
  • [MeSH-major] Bone Marrow / pathology. Clone Cells / pathology. Epstein-Barr Virus Infections / pathology. Histiocytes / pathology. Lymphoma, B-Cell / pathology. T-Lymphocytes / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621841.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


56. Bleyer A, Viny A, Barr R: Cancer in 15- to 29-year-olds by primary site. Oncologist; 2006 Jun;11(6):590-601
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hodgkin lymphoma, melanoma, testis cancer, female genital tract malignancies, thyroid cancer, soft-tissue sarcomas, non-Hodgkin lymphoma, leukemia, brain and spinal cord tumors, breast cancer, bone sarcomas, and nongonadal germ cell tumors account for 95% of the cancers in this age group.
  • This increase is declining and at the older end of the age range appears to be returning to the incidence of the 1970s.
  • African-Americans, American Indian/Alaska Natives had a worse prognosis than white non-Hispanics and Asians.
  • MORTALITY & SURVIVAL: At the beginning of the last quarter century, the diagnosis of cancer in 15- to 29-year-olds carried a more favorable prognosis, on the average, relative to cancer at other ages.
  • Among 15- to 29-year-olds, non-Hispanic whites had the best survival and African Americans/blacks had the worst survival, with a 20% difference apparent by 5 years.
  • Melanoma, cervical carcinoma and Kaposi sarcoma, non-Hodgkin lymphoma, Hodgkin and Burkitt lymphomas accounting for the majority of environmentally induced malignancies (ultraviolet light, human papillomavirus, human immunodeficiency virus, and Epstein-Barr virus, respectively).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794238.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 7
  •  go-up   go-down


57. Campidelli C, Gazzola A, Vitone F, Pileri SA, Tumwine L: HIV infection and c-MYC status in endemic Burkitt lymphoma. Hum Pathol; 2008 Sep;39(9):1408-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV infection and c-MYC status in endemic Burkitt lymphoma.
  • [MeSH-major] Burkitt Lymphoma / pathology. Genes, myc / genetics. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18706352.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM: Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer; 2008 Dec 1;123(11):2658-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited.
  • Endemic Burkitt lymphoma (BL) is etiologically associated with Epstein-Barr virus and ecologically linked to Plasmodium falciparum malaria.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Hum Genet. 1997 Nov;101(1):1-5 [9385359.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jun;50(6):1125-6 [18300307.001]
  • [Cites] Lancet Oncol. 2008 Apr;9(4):319 [18380064.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1319-23 [18000823.001]
  • [Cites] Trop Med Int Health. 2007 Aug;12(8):936-43 [17697088.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Am J Trop Med Hyg. 2006 Aug;75(2):219-25 [16896122.001]
  • [Cites] Nat Genet. 1993 Sep;5(1):56-61 [8220424.001]
  • [Cites] IARC Sci Publ. 1985;(60):177-86 [3905588.001]
  • [Cites] IARC Sci Publ. 1985;(60):155-64 [4065944.001]
  • [Cites] IARC Sci Publ. 1984;(63):665-74 [6536627.001]
  • [Cites] J Clin Immunol. 1985 Mar;5(2):65-77 [3886684.001]
  • [Cites] Int J Cancer. 1980 Feb 15;25(2):197-203 [7390649.001]
  • [Cites] Int J Cancer. 1979 Mar 15;23(3):330-6 [437917.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Community Dent Health. 2005 Sep;22(3):146-50 [16161877.001]
  • [Cites] West Afr J Med. 2005 Apr-Jun;24(2):139-42 [16092315.001]
  • [Cites] Early Hum Dev. 2005 Jan;81(1):123-9 [15707724.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):738-46 [15581545.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Br J Cancer. 1969 Jun;23(2):235-46 [5788031.001]
  • [Cites] Br Med J. 1971 May 29;2(5760):491-2 [4325452.001]
  • [Cites] Lancet. 1974 Jul 6;2(7871):19-22 [4134408.001]
  • [Cites] Ann Intern Med. 1975 Jul;83(1):31-6 [1147436.001]
  • [Cites] Br J Cancer. 1977 May;35(5):668-73 [861150.001]
  • [Cites] Br J Cancer. 1978 Jan;37(1):109-22 [619954.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • (PMID = 18767045.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010150-08; United States / NCI NIH HHS / CP / N02CP31003; United States / NCI NIH HHS / CP / N02-CP-31003; United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS54919; NLM/ PMC2574984
  •  go-up   go-down


59. Ribeiro RC, Sandlund JT: Burkitt lymphoma in African children: a priority for the global health agenda? Pediatr Blood Cancer; 2008 Jun;50(6):1125-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in African children: a priority for the global health agenda?
  • [MeSH-major] Burkitt Lymphoma / therapy. Developing Countries. International Cooperation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2008 Jun;50(6):1138-42 [18213709.001]
  • (PMID = 18300307.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Erber E, Maskarinec G, Lim U, Kolonel LN: Dietary vitamin D and risk of non-Hodgkin lymphoma: the multiethnic cohort. Br J Nutr; 2010 Feb;103(4):581-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary vitamin D and risk of non-Hodgkin lymphoma: the multiethnic cohort.
  • The present study explored the association between dietary vitamin D and non-Hodgkin's lymphoma (NHL) risk.
  • The multiethnic cohort (MEC) includes more than 215 000 Caucasians, African Americans, Native Hawaiians, Japanese Americans and Latinos, aged 45-75.
  • Vitamin D intake was not associated with NHL risk in the entire cohort (P(trend) = 0.72 for men and P(trend) = 0.83 for women), but significantly lowered disease risk in African American women (hazard ratio (HR) = 0.50, 95 % CI: 0.28, 0.90, P(trend) = 0.03) and was borderline protective in African American men (HR = 0.68; 95 % CI: 0.39, 1.19; P(trend) = 0.31) when the highest to the lowest tertile was compared.
  • In NHL subtype analyses, a 19, 36 and 32 % lowered risk, although not significant, was observed for diffuse large B-cell lymphoma, follicular lymphoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in women, respectively.
  • High dietary intake of vitamin D did not show a protective effect against NHL within the MEC except among African Americans, possibly because vitamin D production due to sun exposure is limited in this population.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • MedlinePlus Health Information. consumer health - Vitamin D Deficiency.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2004 Dec 30;23(24):3803-20 [15580597.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] J Nutr. 2005 Oct;135(10):2478-85 [16177216.001]
  • [Cites] Mayo Clin Proc. 2006 Mar;81(3):353-73 [16529140.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):713-8 [16556850.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Am J Epidemiol. 2006 Dec 15;164(12):1222-32 [17005624.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):396-400 [17337644.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):346-57 [10695593.001]
  • [Cites] Am J Epidemiol. 2000 Feb 15;151(4):358-70 [10695594.001]
  • [Cites] Am J Epidemiol. 2002 Oct 1;156(7):669-75 [12244036.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):454-66 [14977641.001]
  • [Cites] J Am Diet Assoc. 2004 Jun;104(6):980-3 [15175600.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S [15585788.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1717S-20S [15585793.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Cancer Causes Control. 2005 Mar;16(2):83-95 [15868450.001]
  • (PMID = 19781122.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / PC / N01 PC035137; United States / NCI NIH HHS / CA / N01PC35137; None / None / / N01 PC035137; United States / NCI NIH HHS / CA / R37 CA54281; United States / NCI NIH HHS / CA / R37 CA054281-17; United States / NCI NIH HHS / CA / CA054281-17; United States / NCI NIH HHS / PC / N01-PC-35 137; United States / NCI NIH HHS / CA / R37 CA054281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS231119; NLM/ PMC2935689
  •  go-up   go-down


61. Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC 3rd, Janz S: Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res; 2005 Feb 15;65(4):1306-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The insertion of Myc(His) mimicked both the human t(8;14)(q24;q32) translocation that results in the activation of MYC in human endemic Burkitt lymphomas and the homologous mouse T(12;15) translocation that deregulates Myc in certain mouse plasmacytomas.
  • Beginning at the age of 6 months, Myc(His) transgenic mice developed B-cell and plasma neoplasms, such as IgM(+) lymphoblastic B-cell lymphomas, Bcl-6(+) diffuse large B-cell lymphomas, and CD138(+) plasmacytomas, with an overall incidence of 68% by 21 months.
  • Molecular studies of lymphoblastic B-cell lymphoma, the most prevalent neoplasm (50% of all tumors), showed that the lymphomas were clonal, overexpressed Myc(His), and exhibited the P2 to P1 promoter shift in Myc expression, a hallmark of MYC/Myc deregulation in human endemic Burkitt lymphoma and mouse plasmacytoma.
  • Only 1 (6.3%) of 16 lymphoblastic B-cell lymphomas contained a BL-typical point mutation in the amino-terminal transactivation domain of Myc(His), suggesting that most of these tumors are derived from naive, pregerminal center B cells.
  • Twelve (46%) of 26 lymphoblastic B-cell lymphomas exhibited changes in the p19(Arf)-Mdm2-p53 tumor suppressor axis, an important pathway for Myc-dependent apoptosis.
  • We conclude that Myc(His) insertion into Igh predictably induces B-cell and plasma-cell tumors in mice, providing a valuable mouse model for understanding the transformation-inducing consequences of the MYC/Myc-activating endemic Burkitt lymphoma t(8;14)/plasmacytoma T(12;15) translocation.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 8 / genetics. Genes, myc / genetics. Immunoglobulin Heavy Chains / genetics. Lymphoma, B-Cell / genetics. Plasmacytoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. B-Lymphocytes / physiology. Burkitt Lymphoma / genetics. Burkitt Lymphoma / pathology. Disease Models, Animal. Genes, Tumor Suppressor / physiology. Humans. Mice. Molecular Sequence Data. Point Mutation. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Promoter Regions, Genetic. Transgenes


62. Maskarinec G, Erber E, Gill J, Cozen W, Kolonel LN: Overweight and obesity at different times in life as risk factors for non-Hodgkin's lymphoma: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev; 2008 Jan;17(1):196-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overweight and obesity at different times in life as risk factors for non-Hodgkin's lymphoma: the multiethnic cohort.
  • Obesity may increase the risk for non-Hodgkin's lymphoma (NHL) through an inflammatory pathway.
  • We explored the relation of NHL with body size at different times in life within the Multiethnic Cohort that includes African Americans, Caucasians, Japanese, Latinos, and Native Hawaiians.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, B-Cell / etiology. Lymphoma, Follicular / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, T-Cell / etiology. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187389.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA 90956; United States / NCI NIH HHS / CA / R37 CA 54281
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


63. Moormann AM, Heller KN, Chelimo K, Embury P, Ploutz-Snyder R, Otieno JA, Oduor M, Münz C, Rochford R: Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer; 2009 Apr 1;124(7):1721-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses.
  • Endemic Burkitt lymphoma (eBL) is the most common childhood cancer in equatorial Africa and is linked to Epstein-Barr virus (EBV) and Plasmodium falciparum coinfections early in life.
  • In addition, CD4(+) T cell responses to a malaria protein, merozoite surface protein 1, were present in lymphoma patients.
  • This study demonstrates a selective loss of EBNA1-specific T cell responses in children with eBL and suggests a potential immunotherapeutic target for this EBV-associated lymphoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):461-73 [11313005.001]
  • [Cites] J Immunol. 2008 Feb 1;180(3):1451-61 [18209040.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1371-4 [12958359.001]
  • [Cites] J Virol. 2003 Nov;77(22):12088-104 [14581546.001]
  • [Cites] Infect Immun. 2003 Dec;71(12):6766-74 [14638762.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):459-70 [14769850.001]
  • [Cites] Tissue Antigens. 2004 Apr;63(4):293-325 [15009803.001]
  • [Cites] IARC Sci Publ. 1985;(60):165-76 [2998987.001]
  • [Cites] Nature. 1995 Jun 22;375(6533):685-8 [7540727.001]
  • [Cites] Immunity. 1997 Dec;7(6):791-802 [9430224.001]
  • [Cites] Nature. 1999 Jul 1;400(6739):73-7 [10403251.001]
  • [Cites] East Afr Med J. 2004 Aug;(8 Suppl):S68-77 [15622605.001]
  • [Cites] J Infect Dis. 2005 Apr 15;191(8):1233-8 [15776368.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3166-74 [16014568.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):165-72 [16415871.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1459-67 [16597877.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):121-7 [17019706.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1138-46 [16985171.001]
  • [Cites] J Infect Dis. 2007 Mar 15;195(6):799-808 [17299709.001]
  • [Cites] J Immunol. 2002 Aug 1;169(3):1593-603 [12133989.001]
  • (PMID = 19089927.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108609; United States / NIAID NIH HHS / AI / AI4390; United States / FIC NIH HHS / TW / D43 TW006576; United States / NCI NIH HHS / CA / R01 CA101741; United States / NIAID NIH HHS / AI / U01 AI043906; United States / NIAID NIH HHS / AI / R01 AI043906; United States / NCI NIH HHS / CA / R01 CA134051; United States / NIAID NIH HHS / AI / K08 AI051565; United States / NCI NIH HHS / CA / CA101741; United States / FIC NIH HHS / TW / D43 TW006576-05; United States / NIAID NIH HHS / AI / K08-AI51565; United States / NIAID NIH HHS / AI / K08 AI051565-05; United States / NCI NIH HHS / CA / CA108609; United States / NCI NIH HHS / CA / R01 CA102667
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS98574; NLM/ PMC2708320
  •  go-up   go-down


64. van Lierop AC, Prescott CA, Fagan JJ, Sinclair-Smith CC: Is diagnostic tonsillectomy indicated in all children with asymmetrically enlarged tonsils? S Afr Med J; 2007 May;97(5):367-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 13 patients (7.6%) diagnosed as having clinically asymmetrically enlarged tonsils had no significant pathological diagnosis.
  • In the patients with symmetrical tonsils there were 2 abnormal pathological findings (tuberculosis of the adenoids and T-cell lymphoma of the tonsils and adenoids).

  • MedlinePlus Health Information. consumer health - Tonsillitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17599220.001).
  • [ISSN] 0256-9574
  • [Journal-full-title] South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • [ISO-abbreviation] S. Afr. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


65. Ocheni S, Okafor CO, Emodi IJ, Ibegbulam OG, Olusina DB, Ikefuna AN, Nnakenyi EF: Spectrum of childhood malignancies in Enugu, Nigeria (1999-2004). Afr J Med Med Sci; 2005 Dec;34(4):371-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The three commonest malignancies were lymphomas 33 (41.2%), sarcomas 12 (15.2%) and nephroblastomas 12 (15.2%).
  • Burkitt's lymphoma remains the commonest specific childhood malignancy in this environment constituting 19 (57.6%) of all the lymphomas and 24.1% of all the cancers seen.
  • [MeSH-minor] Adolescent. Age Distribution. Burkitt Lymphoma / epidemiology. Child. Child, Preschool. Female. Hospitals, University. Humans. Infant. Infant, Newborn. Lymphoma / epidemiology. Male. Nigeria / epidemiology. Registries. Retrospective Studies. Sex Distribution

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752668.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


66. Lukande R, Wabinga HR, Tumwine LK: Burkitt's lymphoma in Uganda: the role of immunohistochemistry in diagnosis. East Afr Med J; 2008 May;85(5):207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in Uganda: the role of immunohistochemistry in diagnosis.
  • BACKGROUND: Haematoxylin and eosin staining has remained the standard diagnostic method for Burkitt's lymphoma.
  • Ancillary tests including immunohistochemistry, not widely available in developing countries, are important tools in verifying the diagnosis of lymphomas with equivocal morphological findings.
  • OBJECTIVE: To evaluate the reliability of haematoxylin and eosin staining in the diagnosis of Burkitt's lymphoma using immunohistochemistry as the gold standard.
  • SUBJECTS: One hundred and thirty eight formalin fixed paraffin embedded biopsies of Burkitt's lymphoma diagnosed from January 2001 to December 2005.
  • CONCLUSION: Histology using haematoxylin and eosin staining is sensitive in the diagnosis of Burkitt's lymphoma but not very specific.
  • [MeSH-major] Antigens, CD20 / analysis. Biomarkers, Tumor / analysis. Burkitt Lymphoma / diagnosis. Eosine Yellowish-(YS). Hematoxylin. Immunohistochemistry / methods. Ki-67 Antigen / analysis

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814530.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


67. Otoh EC, Johnson NW, Ajike SO, Mohammed A, Danfillo IS, Jallo PH: Primary head and neck cancers in North -Western Nigeria. West Afr J Med; 2009 Jul-Aug;28(4):227-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinomas (55%), lymphomas (23%) and retino-blastomas (10%) were the most common cancers.
  • A significant increase was noted in the occurrence of conjunctival squamous cell carinoma (SCC) and Non-Hodgkins Lymphoma NHL when comparing the periods pre- and post- advent of HIV/ AIDS in Nigeria in 1986.
  • Comparing the two periods, there was a reduction in the ages of occurrence of conjunctival SCC; Non-Hodgkins Lymphoma (NHL), Kaposis sarcoma (KS) and nasopharyngeal carcinoma, a rise in the occurrence of nasopharyngeal carcinoma and a significant drop in the occurrence of Burkitt lymphoma.


68. Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer; 2008 Aug 15;113(4):791-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004.
  • BACKGROUND: Mantle cell lymphoma (MCL) is a distinct subtype of B-cell non-Hodgkin's lymphoma.
  • METHODS: Patients diagnosed with MCL between 1992 and 2004 were identified from the Surveillance, Epidemiology, and End Results (SEER) Tumor registries.
  • RESULTS: Of the 87,166 patients diagnosed with non-Hodgkin's lymphoma during the 13-year period between 1992 and 2004, 2459 (2.8%) had confirmed MCL.
  • The median age at diagnosis was 68 years.
  • The incidence of MCL was higher in men (0.84 of 100,000) than in women (0.34 of 100,000) (P < .05), and was higher in Caucasians (0.61 of 100,000) than in African Americans (0.32 of 100,000).
  • [MeSH-major] Lymphoma, Mantle-Cell / epidemiology
  • [MeSH-minor] African Americans. Age Distribution. Aged. European Continental Ancestry Group. Female. Genotype. Humans. Incidence. Male. Middle Aged. Registries. SEER Program. Sex Factors. Survival Rate. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 American Cancer Society
  • (PMID = 18615506.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / AHRQ HHS / HS / R01-HS016743
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


69. Stiller CA: International patterns of cancer incidence in adolescents. Cancer Treat Rev; 2007 Nov;33(7):631-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphomas were the most frequent cancers in western industrialised countries of the northern hemisphere and in the Middle East, and occurred in substantial numbers in all other regions.
  • Hodgkin lymphoma outnumbered non-Hodgkin in western industrialised countries but was relatively rare in most developing countries and in Japan.
  • Kaposi sarcoma was the most frequent cancer in both sub-Saharan African series studied.
  • Total cancer incidence was higher in adolescent males than females, but there was often a female excess in melanoma and thyroid carcinoma, and Hodgkin lymphoma was at least as frequent among females as males in several countries with relatively high incidence.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329031.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


70. Harrison TM, Sikarskie J, Kitchell B, Rosenstein DS, Flaherty H, Fitzgerald SD, Kiupel M: Treatment of malignant lymphoma in an African lion (Panthera leo). J Zoo Wildl Med; 2007 Jun;38(2):333-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of malignant lymphoma in an African lion (Panthera leo).
  • A 14 yr-old male, vasectomized African lion (Panthera leo) exhibited mild weight loss despite adequate appetite.
  • On the basis of hematology and clinical pathology, malignant lymphoma with chronic lymphocytic leukemia was diagnosed.
  • Histologic examination and immunohistochemistry confirmed a small cell peripheral T-cell lymphoma.
  • The lion survived 504 days from initial diagnosis.
  • At necropsy, the only lesions consistent with lymphoma were localized epitheliotrophic infiltrates of small neoplastic T lymphocytes within the nasopharyngeal epithelium and the underlying submucosa observed on microscopic examination.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lions. Lymphoma, T-Cell, Peripheral / veterinary. Splenic Neoplasms / veterinary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679520.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Bain BJ: A ghostly presence-G6PD deficiency. Am J Hematol; 2010 Apr;85(4):271
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adult. African Continental Ancestry Group. Burkitt Lymphoma / drug therapy. Cell Shape. Diagnosis, Differential. Erythrocyte Indices. Erythrocyte Membrane / pathology. Erythrocytes / pathology. Glucosephosphate Dehydrogenase / blood. Heinz Bodies / pathology. Humans. Male


72. Samaila MO: Malignant tumours of childhood in Zaria. Afr J Paediatr Surg; 2009 Jan-Jun;6(1):19-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The five commonest tumours over-all were rhabdomyosarcoma, Burkitt lymphoma, retinoblastoma, non-Hodgkin's lymphoma and nephroblastoma.
  • Lymphomas were the commonest tumours overall while retinoblastoma and Burkitt lymphoma were the commonest tumours affecting children below 5 years and 6-10 years old, respectively, in our centre.
  • [MeSH-major] Lymphoma / epidemiology. Neoplasms / epidemiology. Neoplasms / pathology. Retinal Neoplasms / epidemiology. Retinoblastoma / epidemiology
  • [MeSH-minor] Adolescent. Africa South of the Sahara / epidemiology. Age Distribution. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Nigeria / epidemiology. Sex Distribution

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661660.001).
  • [ISSN] 0974-5998
  • [Journal-full-title] African journal of paediatric surgery : AJPS
  • [ISO-abbreviation] Afr J Paediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


73. Magrath I: Denis Burkitt and the African lymphoma. Ecancermedicalscience; 2009;3:159
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Denis Burkitt and the African lymphoma.
  • Burkitt lymphoma has provided a model for the understanding of the epidemiology, the molecular abnormalities that induce tumours, and the treatment of other lymphomas.
  • In addition, it is time to re-explore, with modern techniques, some of the questions that were raised some 50 years ago shortly after Burkitt's first description, as well as new questions that can be asked only in the light of modern understanding of the immune system and the molecular basis of tumor development.
  • The African lymphoma has taught us much, but there is a great deal still to be learned.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22276020.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3224008
  •  go-up   go-down


74. Tumwine JK: African Health Sciences. Editor's choice. Afr Health Sci; 2006 Jun;6(2):67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] African Health Sciences. Editor's choice.
  • [MeSH-minor] Africa. Developing Countries. Herbal Medicine. Humans. Lymphoma, AIDS-Related

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):76-80 [16916295.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):81-5 [16916296.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):85 [16916297.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):86-92 [16916298.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):93-7 [16916299.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):127-30 [16916306.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):104-7 [16916301.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):108-12 [16916302.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):113-7 [16916303.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):118-9 [16916304.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):120-6 [16916305.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):98-103 [16916300.001]
  • (PMID = 16916292.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Editorial; Introductory Journal Article
  • [Publication-country] Uganda
  • [Other-IDs] NLM/ PMC1831973
  •  go-up   go-down


75. Shine NP, O'Leary G, Blake SP: Parotid lymphomas--clinical and computed tomographic imaging features. S Afr J Surg; 2006 May;44(2):60, 62-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid lymphomas--clinical and computed tomographic imaging features.
  • OBJECTIVE: To review the clinical presentation and computed tomography (CT) imaging characteristics of all parotid lymphomas diagnosed at the study institution over a 7-year period.
  • DESIGN: Retrospective chart review of parotid lymphomas diagnosed between 1997 and 2004.
  • After retrospective chart review, a total of 10 patients with histologically proven parotid lymphoma were included in the study, 8 of whom had CT scans available for assessment.
  • RESULTS: Ten patients with histologically proven lymphoma of the parotid gland were identified from among 121 patients with parotid neoplasms, an incidence in this series of 8.3%.
  • All lymphomas were of non-Hodgkin's type.
  • CONCLUSION: Lymphoma has a clinical presentation similar to other neoplasms arising within the parotid gland.
  • A history of less than 4 months may suggest the possibility of lymphoma.
  • Multifocality and associated adenopathy are associated with, but not exclusive to, parotid lymphoma.
  • Although poor tumour boundary definition on CT imaging is a strong predictor of malignancy, no pathognomonic finding specific for lymphoma has been identified.
  • The potential diagnosis of parotid lymphoma should be considered in all patients who present with a parotid mass.
  • [MeSH-major] Lymphoma / radiography. Parotid Neoplasms / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878511.001).
  • [ISSN] 0038-2361
  • [Journal-full-title] South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie
  • [ISO-abbreviation] S Afr J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


76. Kamulegeya A, Kalyanyama BM: Oral maxillofacial neoplasms in an East African population a 10 year retrospective study of 1863 cases using histopathological reports. BMC Oral Health; 2008;8:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral maxillofacial neoplasms in an East African population a 10 year retrospective study of 1863 cases using histopathological reports.
  • Overall 67.28% of the diagnoses recorded were malignant with Kaposi's sarcoma (21.98%), Burkiits lymphoma (20.45%), and squamous cell carcinoma (15.22%) dominating that group while ameloblastoma (9.23%), fibromas (7.3%) and pleomorphic adenoma (4.95%) dominated the benign group.The high frequency of malignancies could be due to inclusion criteria and the clinical practice of selective histopathology investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Public Health. 2006 Dec;96(12):2194-200 [17077408.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] WMJ. 2006 Sep;105(6):32-5 [17042417.001]
  • [Cites] BMC Oral Health. 2006;6:12 [16916469.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Sep;64(9):1343-52 [16916667.001]
  • [Cites] J Oral Pathol Med. 2006 Aug;35(7):392-401 [16827841.001]
  • [Cites] East Afr Med J. 2006 Mar;83(3):62-8 [16771101.001]
  • [Cites] Adv Dent Res. 2006;19(1):57-62 [16672551.001]
  • [Cites] East Afr Med J. 2005 Sep;82(9 Suppl):S135-43 [16619689.001]
  • [Cites] Minerva Stomatol. 2006 Apr;55(4):209-14 [16618995.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):543-50 [16537714.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Oral Oncol. 2006 Feb;42(2):184-9 [16256417.001]
  • [Cites] Br J Oral Maxillofac Surg. 2005 Jun;43(3):226-31 [15888358.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 May;99(5):598-602 [15829884.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer. 1965 Feb;18:205-15 [14254077.001]
  • [Cites] Cancer Res. 1963 Oct;23:1514-8 [14072690.001]
  • [Cites] East Afr Med J. 1956 Oct;33(10):383-6; passim [13375488.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Dec;86(6):707-14 [9868729.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Dec;84(6):672-5 [9431538.001]
  • [Cites] East Afr Med J. 1997 Feb;74(2):65-8 [9185386.001]
  • [Cites] East Afr Med J. 1997 Jan;74(1):33-6 [9145575.001]
  • [Cites] Cent Afr J Med. 1996 Apr;42(4):102-8 [8791865.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):200-3 [8567117.001]
  • [Cites] Int J Oral Maxillofac Surg. 1995 Aug;24(4):293-7 [7490493.001]
  • [Cites] Pathol Res Pract. 1990 Oct;186(5):555-81 [1962854.001]
  • [Cites] J Am Dent Assoc. 1968 Apr;76(4):761-6 [5237768.001]
  • [Cites] Br J Cancer. 1969 Mar;23(1):31-8 [5787651.001]
  • [Cites] J Contemp Dent Pract. 2004 Aug 15;5(3):16-27 [15318253.001]
  • [Cites] Int J Oral Maxillofac Surg. 2003 Feb;32(1):78-83 [12653238.001]
  • [Cites] Ann Acad Med Singapore. 1999 Sep;28(5):665-71 [10597351.001]
  • (PMID = 18651958.001).
  • [ISSN] 1472-6831
  • [Journal-full-title] BMC oral health
  • [ISO-abbreviation] BMC Oral Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2561014
  •  go-up   go-down


77. Gutiérrez-García L, Medina Ramos N, García Rodríguez R, Barber MA, Arias MD, García JA: Bilateral ovarian Burkitt's lymphoma. Eur J Gynaecol Oncol; 2009;30(2):231-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian Burkitt's lymphoma.
  • Primary ovarian lymphoma is a rare entity.
  • Histology confirmed Epstein-Barr virus-positive bilateral Burkitt's lymphoma.
  • Endemic Burkitt's lymphoma has a predilection for the female genital tract, manifesting itself clinically as a pelvic mass and less frequently as a menstrual disorder.
  • It is a rare entity in our environment but should be kept in mind when treating patients of African origin.
  • [MeSH-major] Burkitt Lymphoma / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19480266.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


78. Wu XC, Andrews P, Chen VW, Groves FD: Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences. Cancer Epidemiol; 2009 Nov;33(5):337-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of extranodal non-Hodgkin lymphomas among whites, blacks, and Asians/Pacific Islanders in the United States: anatomic site and histology differences.
  • BACKGROUND: Extranodal non-Hodgkin lymphoma (NHL) accounts for much of the increase in NHL incidence in the past three decades in the United States, but its descriptive epidemiology is scarce in the literature.
  • We grouped anatomic sites of extranodal NHLs according to the Surveillance, Epidemiology, and End Results (SEER) site recodes, and histology subtypes according to the nested classification of lymphoid neoplasms developed by the Pathology Working Group of the International Lymphoma Epidemiology Consortium.
  • The significant exceptions are: API men had a 40% higher rate of marginal zone lymphoma (MZL) than white men, and API women had a 12% higher rate of diffuse large B-cell lymphoma (DLBCL) than white women.
  • The rates of all T-cell extranodal NHLs combined and peripheral T-cell lymphoma (PTCL) among black women exceeded those of white women by 46% and 18%, respectively.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. African Americans. Age Distribution. Aged. Aged, 80 and over. Asian Americans. European Continental Ancestry Group. Female. Humans. Incidence. Male. Middle Aged. Oceanic Ancestry Group. Registries. SEER Program. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19853554.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


79. Abdulkareem FB, Faduyile FA, Daramola AO, Rotimi O, Banjo AA, Elesha SO, Anunobi CC, Akinde OR, Abudu EK: Malignant gastrointestinal tumours in south western Nigeria: a histopathologic analysis of 713 cases. West Afr J Med; 2009 May;28(3):173-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: About 80% (578 cases) of all the 713 malignant GIT tumours were epithelial; sarcomas, carcinoid and non-Hodgkin's lymphoma being less common.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrointestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20306734.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


80. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E: Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci; 2007 Sep;7(3):166-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma in Africa, a review of the epidemiology and etiology.
  • Burkitt's lymphoma (BL) was first described in Eastern Africa, initially thought to be a sarcoma of the jaw.
  • Shortly it became well known that this was a distinct form of Non Hodgkin's lymphoma.
  • Evidence for a causal relationship between EBV and BL in the endemic form is fairly strong.
  • The emergence of HIV and a distinct subtype of BL in HIV infected have brought a new dimension to the disease particularly in areas where both HIV and BL are endemic.
  • [MeSH-major] Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / etiology

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • HIV InSite. treatment guidelines - Malaria and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):481-5 [10508483.001]
  • [Cites] Lancet. 1991 May 18;337(8751):1190 [1673740.001]
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1878-85 [10711230.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):687-91 [11340573.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1566-9 [12771923.001]
  • [Cites] J Ethnopharmacol. 2003 Sep;88(1):19-44 [12902048.001]
  • [Cites] J Ethnopharmacol. 2003 Oct;88(2-3):279-86 [12963156.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Toxicon. 2004 Sep 15;44(4):417-30 [15302524.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1420-7 [15368330.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):757-68 [15510157.001]
  • [Cites] Science. 1967 Sep 1;157(3792):1064-5 [6036237.001]
  • [Cites] J Virol. 1967 Aug;1(4):830-7 [4316231.001]
  • [Cites] J Natl Cancer Inst. 1971 Apr;46(4):861-71 [4324816.001]
  • [Cites] J Natl Cancer Inst. 1973 May;50(5):1163-73 [4351392.001]
  • [Cites] IARC Sci Publ. 1975;(11 Pt 2):3-16 [191375.001]
  • [Cites] Nature. 1979 Jul 19;280(5719):244-5 [221841.001]
  • [Cites] Lancet. 1981 Jul 18;2(8238):115-8 [6113482.001]
  • [Cites] Int J Cancer. 1982 Apr 15;29(4):397-400 [6282763.001]
  • [Cites] Cancer Lett. 1983 Jun;19(2):199-205 [6309363.001]
  • [Cites] Lancet. 1987 May 30;1(8544):1257-8 [2884382.001]
  • [Cites] Am J Epidemiol. 1989 Apr;129(4):740-52 [2923122.001]
  • [Cites] Trop Geogr Med. 1990 Jul;42(3):255-60 [2293434.001]
  • [Cites] Eur J Cancer. 1991;27(4):504-9 [1827731.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Summer;13(2):222-46 [2069232.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1356-60 [1873787.001]
  • [Cites] Cent Afr J Med. 1992 Jan;38(1):17-25 [1633615.001]
  • [Cites] Curr Opin Oncol. 1992 Oct;4(5):883-93 [1457503.001]
  • [Cites] Semin Cancer Biol. 1992 Oct;3(5):285-95 [1335792.001]
  • [Cites] Br J Cancer. 1993 Dec;68(6):1232-5 [8260378.001]
  • [Cites] Lancet. 1995 May 27;345(8961):1378-9 [7752795.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5279-86 [8652843.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Virol. 1998 Oct;72(10):8105-14 [9733851.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1285-9 [9824108.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:258-69 [14448554.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):738-46 [15581545.001]
  • [Cites] Nat Rev Microbiol. 2005 Feb;3(2):182-7 [15685227.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • (PMID = 18052871.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Uganda
  • [Number-of-references] 50
  • [Other-IDs] NLM/ PMC2269718
  •  go-up   go-down


81. Abinya ON: Burkitt's lymphoma-- what is new? East Afr Med J; 2008 May;85(5):205-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma-- what is new?
  • [MeSH-major] Burkitt Lymphoma

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814529.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; CVAD protocol
  •  go-up   go-down


82. Futagbi G, Welbeck JE, Tetteh JK, Hviid L, Akanmori BD: Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma. Malar J; 2007;6:69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective activation of TCR-gammadelta+ cells in endemic Burkitt's lymphoma.
  • BACKGROUND: The overlap in geographical distribution of Plasmodium falciparum malaria and endemic Burkitt's lymphoma (eBL)--an aggressive Epstein-Barr virus (EBV)-associated B-cell tumour occurring almost exclusively in the tropics--strongly suggests a link between the two diseases.
  • METHODS: Venous blood samples in heparin from 21 eBL patients (mean age: 7.0 years; range: 3-11 years), referred to the Burkitt's Tumour Centre at Korle-Bu Teaching Hospital, Accra and 15 healthy, age and sex matched children, were stained with fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-, R-phycoerythrin (RPE)- and RPE-Cy5-conjugated antibodies (CD3, CD4, CD8, CD25, CD69, CD95, HLA-DR, TCR-gammadelta, Vdelta1, Vdelta3, Vgamma9 and B-cells) and acquired on a flow cytometer.
  • [MeSH-major] Burkitt Lymphoma / immunology. Lymphocyte Activation. Malaria, Falciparum / complications. Malaria, Falciparum / immunology. Receptors, Antigen, T-Cell, gamma-delta / metabolism. T-Lymphocyte Subsets / immunology
  • [MeSH-minor] Child. Child, Preschool. Endemic Diseases. Female. Ghana / epidemiology. Humans. Male

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEMS Microbiol Immunol. 1991 Aug;3(4):219-27 [1931134.001]
  • [Cites] J Immunol. 1992 Dec 15;149(12):3984-9 [1334108.001]
  • [Cites] J Immunol Methods. 1993 Jan 4;157(1-2):135-42 [8423356.001]
  • [Cites] Am J Trop Med Hyg. 1994 Sep;51(3):372-9 [7524374.001]
  • [Cites] Eur J Immunol. 1994 Dec;24(12):3199-204 [7528674.001]
  • [Cites] J Immunol. 1997 Jan 1;158(1):464-74 [8977224.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4359-62 [8926112.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Mar-Apr;16(2):149-58 [10100275.001]
  • [Cites] Am J Trop Med Hyg. 1991 May;44(5):571-7 [2063961.001]
  • [Cites] Int Immunol. 2000 Jun;12(6):797-805 [10837407.001]
  • [Cites] Infect Immun. 2001 May;69(5):3190-6 [11292740.001]
  • [Cites] J Natl Cancer Inst. 1969 Jan;42(1):19-28 [4303830.001]
  • [Cites] Am J Med. 1970 Mar;48(3):279-85 [4190958.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1977;71(5):408-10 [304268.001]
  • [Cites] Clin Exp Immunol. 1978 Apr;32(1):41-5 [352584.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1978 Dec;22(6):662-8 [214405.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):398 [6095098.001]
  • [Cites] Nature. 1984 Nov 29-Dec 5;312(5993):449-50 [6095104.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1262-74 [3114436.001]
  • [Cites] Eur J Immunol. 1991 May;21(5):1249-53 [1674690.001]
  • (PMID = 17521425.001).
  • [ISSN] 1475-2875
  • [Journal-full-title] Malaria journal
  • [ISO-abbreviation] Malar. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  • [Other-IDs] NLM/ PMC1894981
  •  go-up   go-down


83. Chene A, Donati D, Orem J, Mbidde ER, Kironde F, Wahlgren M, Bejarano MT: Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus. Semin Cancer Biol; 2009 Dec;19(6):411-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endemic Burkitt's lymphoma as a polymicrobial disease: new insights on the interaction between Plasmodium falciparum and Epstein-Barr virus.
  • Despite the well-established relationship between endemic Plasmodium falciparum malaria and Epstein-Barr virus (EBV) infection in the genesis of endemic Burkitt's lymphoma (eBL), very little research has examined the interaction between these two pathogens. eBL, the most prevalent childhood cancer in equatorial Africa where malaria is holoendemic, is a high-grade B cell lymphoma characterized by a c-myc translocation and the consistent presence of EBV.
  • African children are infected early in life and most have sero-converted by 3 years of age while sero-conversion tends to occur later in developed countries.
  • Following the observation of EBV reactivation in children living in malaria endemic areas and its relationship with acute malaria infection, we identified the cystein-rich inter-domain region 1 alpha (CIDR1 alpha) of the Plasmodium falciparum membrane protein 1 as a polyclonal B cell activator.
  • The increased viral load and the concomitant polyclonal B cell activation with enhanced B cell survival may augment the risk of eBL development in children living in malaria-endemic areas.
  • [MeSH-major] Burkitt Lymphoma / etiology. Epstein-Barr Virus Infections / complications. Herpesvirus 4, Human / pathogenicity. Malaria, Falciparum / complications. Plasmodium falciparum / pathogenicity

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897039.001).
  • [ISSN] 1096-3650
  • [Journal-full-title] Seminars in cancer biology
  • [ISO-abbreviation] Semin. Cancer Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 100
  •  go-up   go-down


84. Walid MS, Ajjan M, Grigorian AA: Neurosarcoidosis--the great mimicker. J Natl Med Assoc; 2008 Jul;100(7):859-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 22-year-old African-American man presented with inability to gaze laterally.
  • Frozen-section study came suggestive of lymphoma.
  • It is important to keep neurosarcoidosis in mind when making the diagnosis, which often requires biopsy.
  • [MeSH-major] Brain Edema / diagnosis. Craniotomy. Facial Paralysis / etiology. Sarcoidosis / diagnosis
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Prednisone / therapeutic use

  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672565.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; VB0R961HZT / Prednisone
  •  go-up   go-down


85. Sambol E, Patterson D, Rivera R, Borys D, Greco MA, Kaul A, Nadler EP: An appendiceal leiomyoma in a child with acquired immunodeficiency syndrome. Pediatr Surg Int; 2006 Oct;22(10):865-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we present an unusual case of a 12-year-old African American girl with vertically acquired AIDS who presented to the pediatric emergency department with severe diffuse abdominal pain.
  • Our report suggests that smooth muscle tumors of the appendix be included in the differential diagnosis of abdominal masses in children with AIDS.
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Laparoscopy. Laparotomy. Tomography, X-Ray Computed


86. Olowu WA, Adelusola KA, Badmos KB, Aina OJ: Autopsy diagnosis of endemic burkitt lymphoma as the primary etiology of acute renal failure in children. Pediatr Hematol Oncol; 2005 Jun;22(4):315-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autopsy diagnosis of endemic burkitt lymphoma as the primary etiology of acute renal failure in children.
  • Two cases of Burkitt lymphoma are reported who presented atypically with acute renal failure and significant proteinuria as initial features of the lymphoma.
  • The cases underscore the need for high index of suspicion for Burkitt lymphoma in any child with rapidly enlarging kidneys and acute renal failure of obscured origin in parts of the world where Burkitt lymphoma is endemic.
  • [MeSH-major] Acute Kidney Injury / etiology. Burkitt Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Autopsy. Child, Preschool. Diagnosis, Differential. Endemic Diseases. Fatal Outcome. Female. Humans. Kidney Medulla / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020119.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


87. Mohammed A, Malami SA, Calvin B, Abdullahi K: A histopathological study of ovarian neoplasms in children in a tertiary hospital of northern Nigeria. Afr J Paediatr Surg; 2010 May-Aug;7(2):75-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among all the malignant tumours seen in this period, 32% occurred in children, and Burkitt's lymphoma accounted for 31.2% of these.
  • CONCLUSION: Burkitt's lymphoma is the most common childhood ovarian tumour in Zaria, northern Nigeria.
  • [MeSH-major] Burkitt Lymphoma / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Glandular and Epithelial / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20431214.001).
  • [ISSN] 0974-5998
  • [Journal-full-title] African journal of paediatric surgery : AJPS
  • [ISO-abbreviation] Afr J Paediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


88. Omoregie FO, Saheeb BD, Onasanya PO: Periradicular burkitt's lymphoma: a report of 2 cases from Nigeria and review of the literature. Afr J Med Med Sci; 2008 Sep;37(3):279-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periradicular burkitt's lymphoma: a report of 2 cases from Nigeria and review of the literature.
  • This article reports two cases of periradicular Burkitt's lymphoma from Nigeria, to emphasize the difficulties in differentiating the early lesion from other periradicular lesions with similar clinical and radiological findings Case 1, is a 4-year-old boy who presented with a one-month history of a painless, hard, posterior mandibular swelling (right), which was causing loosening and displacement of deciduous teeth (84 and 85).
  • Histopathological examination of periradicular tissues from extracted tooth (85), confirmed the diagnosis of early periradicular B urkitt's lymphoma.
  • Incisional biopsy of the oral lesion at the region of exfoliated left first mandibular molar (36) was useful for histopathological diagnosis of early Burkitt's lymphoma of the jaw.
  • In the face of limited diagnostic tools such as clinico-radiological assessment, cytology or incisional biopsy for incipient periradicular lesions, a high index of suspicion of Burkitt's lymphoma of the jaw may be helpful in early diagnosis and treatment of a lesion, presenting in a child as periradicular radiolucency or mixed radiolucency and radiopacity, with associated loosening and displacement of teeth.
  • [MeSH-major] Burkitt Lymphoma / pathology. Jaw Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982822.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


89. Othieno-Abinya NA, Waweru A, Nyabola LO: Chemotherapy induced myelosuppression. East Afr Med J; 2007 Jan;84(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS: Two hundred and two solid tumour and lymphoma patients treated with pulsed chemotherapy at Hurlingham Oncology Clinic and those treated by the same service at the Nairobi Hospital.
  • [MeSH-major] Carcinoma / drug therapy. Granulocyte Colony-Stimulating Factor / therapeutic use. Lymphoma / drug therapy. Neutropenia / chemically induced. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633579.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kenya
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


90. Tortevoye P, Moutel G, Tuppin P, Plancoulaine S, Joubert M, Hervé C, Gessain A: [Analysis of the ethical issues raised by a ten-year epidemiology program in French Guiana: limitations of the current legal framework and solutions adopted]. Rev Epidemiol Sante Publique; 2007 Dec;55(6):413-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Analyse des enjeux éthiques soulevés au cours d'un programme de recherche épidémiologique de dix années en Guyane française : limites de l'encadrement actuel et solutions adoptées.
  • This ethnic group of African descent is highly endemic for HTLV-1 and associated adult T cell leukemia/lymphoma.
  • [MeSH-minor] Consumer Participation / legislation & jurisprudence. Educational Status. Ethnic Groups / statistics & numerical data. France. French Guiana / epidemiology. French Guiana / ethnology. Health Promotion / ethics. Health Promotion / legislation & jurisprudence. Humans. Informed Consent / ethics. Informed Consent / legislation & jurisprudence. Leukemia-Lymphoma, Adult T-Cell / epidemiology. Leukemia-Lymphoma, Adult T-Cell / ethnology. Poverty

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18037597.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


91. Kurokawa M, Andela V, Ghosh S, Barreto JE, Harrington W: Zidovudine: a targeted therapy for endemic Burkitt's lymphoma. East Afr Med J; 2005 Sep;82(9 Suppl):S150-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zidovudine: a targeted therapy for endemic Burkitt's lymphoma.
  • BACKGROUND: Although cyclophosphamide based regimens can produce remission rates approaching 60 to 80% in endemic Burkitts lymphoma, relapses and refractory disease are fairly common in developing countries, due to advanced stage disease and cost-constraints in the implementation of optimal chemotherapeutic protocols.
  • OBJECTIVE: To evaluate an affordable, tolerable and targeted approach to chemotherapy for endemic Burkitt's lymphoma as would be desirable in resource poor settings such as Africa.
  • DATA EXTRACTION: A systematic review to identify studies relating to Zidovudine, EBV+ and Burkitt's lymphoma, indicating antiviral agents zidovudine targeting BL in a unique and novel mechanisms.
  • CONCLUSION: Our data suggests that the incorporation of Zidovudine into Burkitt's regimens may enhance tumour kill and abbreviate the duration of treatment necessary for this disease.
  • Furthermore, the addition of the widely available and inexpensive agent hydroxyurea, markedly potentiates the tumorcidal activity of Zidovudine in Epstein Barr virus positive Burkitt's lymphomas.
  • [MeSH-major] Antiviral Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Epstein-Barr Virus Infections / drug therapy. Zidovudine / therapeutic use

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619691.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Kenya
  • [Chemical-registry-number] 0 / Antiviral Agents; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


92. Omoti AE, Omoti CE, Momoh RO: Ophthalmic disorders in adult lymphoma patients in Africa. Middle East Afr J Ophthalmol; 2009 Oct;16(4):252-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ophthalmic disorders in adult lymphoma patients in Africa.
  • CONTEXT: Ocular manifestations of lymphoma are rare events.
  • Most reports of ocular involvement in lymphoma are case reports or reports of a few patients.
  • AIMS: To determine the ophthalmic disorders in adult, African, lymphoma patients.
  • SETTINGS AND DESIGN: A prospective study of ocular disorders in adult patients with lymphoma was conducted at the University of Benin Teaching Hospital, Benin City, Nigeria, between July 2004 and June 2007.
  • RESULTS: A total of 111 patients with hematological malignancies were seen over a period of three years of which 62 (55.85%) had lymphomas.
  • Of these, 51(82.3%) were non-Hodgkin's lymphoma and 11(17.7%) were Hodgkin's lymphoma.
  • Ocular disorders occurred in 16 patients (31.4%) with non-Hodgkin's lymphoma and none of the patients with Hodgkin's lymphoma (Mann-Whitney U-statistic is equal to 7.500, U' is equal to161.50, P< 0.0001).
  • The ocular disorders due to non-Hodgkin's lymphoma were seen as - proptosis in six patients (11.8%), retinopathies in three (5.9%), conjunctival infiltration in three (5.9%), optic atrophy in two (3.9%), keratoconjunctivitis in one (two per cent), desquamating nodular lid lesions in one (two per cent), papilloedema in one (two per cent), and upper lid mass in one (two per cent).
  • CONCLUSIONS: Ophthalmic disorders are relatively common in non-Hodgkin's lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 1997 Apr;74(4):163-8 [9174543.001]
  • [Cites] Ophthalmology. 1999 Jul;106(7):1339-44 [10406618.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Surv Ophthalmol. 2001 May-Jun;45(6):463-71 [11425352.001]
  • [Cites] Ophthalmology. 2002 Sep;109(9):1717-22 [12208722.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):411-8 [12441846.001]
  • [Cites] Ann Afr Med. 2007 Sep;6(3):89-93 [18240494.001]
  • [Cites] Klin Monbl Augenheilkd. 2004 May;221(5):401-3 [15162291.001]
  • [Cites] Med J Malaysia. 2003 Oct;58(4):546-55 [15190631.001]
  • [Cites] Klin Oczna. 2004;106(6):783-7 [15787182.001]
  • [Cites] Clin Lab Haematol. 2005 Oct;27(5):302-6 [16178909.001]
  • [Cites] Can J Ophthalmol. 2005 Oct;40(5):623-6 [16391629.001]
  • [Cites] Ophthalmology. 2003 May;110(5):1057-60 [12750114.001]
  • (PMID = 20404992.001).
  • [ISSN] 0975-1599
  • [Journal-full-title] Middle East African journal of ophthalmology
  • [ISO-abbreviation] Middle East Afr J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2855666
  • [Keywords] NOTNLM ; Lymphoma / Ophthalmic Disorders / Proptosis
  •  go-up   go-down


93. Stefan DC, Stones D, Dippenaar A, Kidd M: Ethnicity and characteristics of Hodgkin lymphoma in children. Pediatr Blood Cancer; 2009 Feb;52(2):182-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ethnicity and characteristics of Hodgkin lymphoma in children.
  • AIM: To identify ethnic group differences in the prognostic of Hodgkin lymphoma (HL) in South African children.
  • PATIENTS AND METHODS: In order to create a larger database, cases were pooled from two South African hospitals: Tygerberg in the Western Cape and Bloemfontein Academic Complex in Free State.
  • The median age at diagnosis was 8 years 11 months.
  • [MeSH-minor] African Continental Ancestry Group. Child. Ethnic Groups. European Continental Ancestry Group. Female. Humans. Male. Prognosis. Retrospective Studies. South Africa / epidemiology. South Africa / ethnology. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [CommentIn] Pediatr Blood Cancer. 2009 Feb;52(2):153-4 [19034906.001]
  • (PMID = 18937324.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


94. Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, Forstin MA, Renaudier P, N'dom P, Malvy D, Dabis F: The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One; 2010;5(1):e8621
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In case-referent studies, odds ratios (OR) were ranging from 21.9 (95% Confidence Interval (CI) 12.5-38.6) to 47.1 (31.9-69.8) for Kaposi sarcoma and from 5.0 (2.7-9.5) to 12.6 (2.2-54.4) for non Hodgkin lymphoma.
  • A record-linkage study conducted in Uganda showed an association between Hodgkin lymphoma and HIV infection with a standardized incidence ratio of 5.7 (1.2-17) although OR in case-referent studies ranged from 1.4 (0.7-2.8) to 1.6 (1.0-2.7).
  • African countries need now to implement well designed population-based studies in order to better describe the spectrum of AIDS-associated malignancies and the most effective strategies for their prevention, screening and treatment.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1995 Aug;21 Suppl 1:S121-4 [8547501.001]
  • [Cites] AIDS. 1996 Apr;10(4):413-7 [8728046.001]
  • [Cites] Br J Ophthalmol. 1996 Jun;80(6):503-8 [8759259.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):587-91 [8774574.001]
  • [Cites] Tumori. 1995 Sep-Oct;81(5):308-14 [8804445.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1996;67:1-424 [9190379.001]
  • [Cites] Lancet. 1997 Nov 15;350(9089):1425-31 [9371165.001]
  • [Cites] Am J Clin Nutr. 2004 Nov;80(5):1106-22 [15531656.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;70:1-492 [9705682.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):37-42 [9709301.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] AIDS. 1998 Oct 1;12(14):1921-5 [9792393.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1521-8 [9836488.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] Int J Gynaecol Obstet. 1999 May;65(2):171-81 [10405062.001]
  • [Cites] Sex Transm Infect. 1999 Apr;75(2):103-6 [10448362.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):489-92 [11054682.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2929-36 [11153674.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):659-61 [11295098.001]
  • [Cites] Int J Cancer. 2001 Jun 1;92(5):622-7 [11340563.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1188-201 [11423251.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):430-5 [11433410.001]
  • [Cites] Int J Gynecol Cancer. 2001 May-Jun;11(3):194-7 [11437924.001]
  • [Cites] Int J Gynaecol Obstet. 2002 Jan;76(1):55-63 [11818095.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] AIDS. 2003 Jan 3;17(1):81-7 [12478072.001]
  • [Cites] Lancet. 2002 Dec 14;360(9349):1921-6 [12493258.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] Sex Transm Dis. 2003 Feb;30(2):137-42 [12567172.001]
  • [Cites] J Womens Health (Larchmt). 2003 Apr;12(3):227-32 [12804353.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Apr;19(2):269-76 [15778115.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5224-8 [16051964.001]
  • [Cites] Cancer. 2005 Oct 1;104(7):1505-11 [16104038.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):985-90 [16106415.001]
  • [Cites] Rev Med Interne. 2006 Mar;27(3):227-35 [16337065.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):914-9 [16565210.001]
  • [Cites] BMC Cancer. 2006;6:135 [16719902.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):355-62 [16832413.001]
  • [Cites] Afr Health Sci. 2006 Jun;6(2):69-75 [16916294.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):642-8 [16868538.001]
  • [Cites] Cancer Lett. 2006 Nov 28;244(1):1-7 [16542773.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Transplant Proc. 2006 Dec;38(10):3533-5 [17175324.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] J Viral Hepat. 2007 Mar;14(3):183-8 [17305884.001]
  • [Cites] Pediatr Blood Cancer. 2007 May;48(5):515-20 [16794998.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):407.e1-8; discussion 407.e8-9 [17403438.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1480-3 [17437020.001]
  • [Cites] Gynecol Obstet Invest. 2007;63(4):222-8 [17191009.001]
  • [Cites] J Med Virol. 2007 Jun;79(6):758-65 [17457908.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2008 Jan 11;22(2):301-6 [18097233.001]
  • [Cites] Cancer Causes Control. 2008 Mar;19(2):147-53 [17992576.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 [18354839.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2260-5 [18241034.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2590-3 [18224690.001]
  • [Cites] J Med Virol. 2008 May;80(5):847-55 [18360898.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Lancet. 2008 May 3;371(9623):1504 [18456099.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2583-8 [10630528.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • [Cites] J Natl Med Assoc. 2000 Jun;92(6):301-5 [10918766.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2401-8 [9635533.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] Bull Cancer. 2003 May;90(5):387-92 [12850760.001]
  • [Cites] J Infect Dis. 2003 Aug 15;188(4):555-63 [12898443.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):84-90 [14501799.001]
  • [Cites] Int J STD AIDS. 2003 Oct;14(10):647-51 [14596765.001]
  • [Cites] Hepatology. 2004 Jan;39(1):211-9 [14752840.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):638-45 [14760378.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):317-24 [15241829.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):468-76 [15314517.001]
  • [Cites] Lancet. 1981 Sep 19;2(8247):598-600 [6116083.001]
  • [Cites] Lancet. 1982 May 1;1(8279):1026-7 [6122840.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373-5 [2989677.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1987 Aug 14;36 Suppl 1:1S-15S [3039334.001]
  • [Cites] Lancet. 1990 Jul 7;336(8706):51-2 [1973230.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Ann Intern Med. 1992 Aug 15;117(4):309-11 [1637026.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Int J Cancer. 1993 Apr 22;54(1):26-36 [8478145.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 1;85(17):1382-97 [8350362.001]
  • [Cites] Int J Cancer. 1994 Oct 1;59(1):20-4 [7927898.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] AIDS. 1995 Jan;9(1):57-63 [7893442.001]
  • [Cites] Lancet. 1995 May 27;345(8961):1378-9 [7752795.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):29-36 [7558448.001]
  • (PMID = 20066157.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / U01 AI069919
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2799672
  •  go-up   go-down


95. Hosny G, Farahat N, Hainaut P: TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma. Cancer Lett; 2009 Mar 18;275(2):234-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
  • Mutations of P53 have been reported as common mutations in solid tumours, including non-Hodgkin lymphoma, NHL, and have been implicated in drug resistance, aggression and poor prognosis.
  • Circulating free DNA (CFDNA) has been shown to be a good source of liver tissue-derived DNA in African and Asian patients with chronic liver disease or hepatocellular carcinoma, HCC.
  • CONCLUSION: Our findings of higher DNA concentrations with some p53 mutations in CFDNA from patients with NHL that match the previous reported p53 mutations from tumour DNA may hold promises that CFDNA may serve as a convenient source of tumour-derived DNA to serve as a promising tool of a non-invasive, low-cost new strategy for earlier detection, diagnosis and follow up of the disease.
  • [MeSH-major] DNA / blood. Lymphoma, Non-Hodgkin / genetics. Mutation. Tumor Suppressor Protein p53 / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19046801.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Tumor Suppressor Protein p53; 9007-49-2 / DNA
  •  go-up   go-down


96. Klumb CE, Magluta EP, Rezende LM, Apa AG, Alonso JF, Maia RC: Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil. Am J Hematol; 2007 Mar;82(3):238-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoblastoma-related geneRb2/p130 are rarely mutated in Burkitt's lymphoma from Brazil.
  • It has been suggested that alterations of cell cycle genes probably contribute to the pathogenesis of endemic Burkitt's lymphoma (BL) in addition to c-MYC translocation.
  • Mutations disrupting the normal nuclear localization signal of the retinoblastoma-related gene Rb2/p130 have been documented in BL cell lines and primary tumors from endemic areas.
  • [MeSH-major] Burkitt Lymphoma / genetics. Point Mutation. Retinoblastoma-Like Protein p130 / genetics

  • Genetic Alliance. consumer health - Retinoblastoma.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16955460.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RBL2 protein, human; 0 / Retinoblastoma-Like Protein p130; 9007-49-2 / DNA
  •  go-up   go-down


97. Valenzuela-Salas B, Dean-Ferrer A, Alamillos-Granados FJ: Burkitt's lymphoma: a child's case presenting in the maxilla. Clinical and radiological aspects. Med Oral Patol Oral Cir Bucal; 2010 May;15(3):e479-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma: a child's case presenting in the maxilla. Clinical and radiological aspects.
  • Burkitt's lymphoma (BL) is a neoplasm which, despite its very aggressive behaviour is potentially curable.
  • BL belongs to the non-Hodgkin lymphomas group, and is the first human tumour undoubtedly related to a viral origin (Epstein-Barr virus).
  • Two main clinical subtypes are recognized: endemic or African type, and sporadic type; HIV associated BL constitutes a third type.
  • Although common in endemic BL, maxillary involvement is rare in sporadic cases.
  • This, together with the clinical lack of specificity associated to this location, makes diagnosis difficult.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Maxillary Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038882.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


98. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB: Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A; 2006 Oct 3;103(40):14935-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.
  • For example, endemic Burkitt lymphoma (BL) classically presents as a monoclonal, c-myc-translocation-positive tumor in which every cell carries EBV as an EBNA1-only (Latency I) infection; such homogeneity among EBV-positive cells, and the lack of EBV-negative comparators, hampers attempts to understand EBV's role in BL pathogenesis.
  • Here, we describe an endemic BL that was unusually heterogeneous at the single-cell level and, in early passage culture, yielded a range of cellular clones, all with the same c-myc translocation but differing in EBV status.
  • [MeSH-major] Apoptosis. Burkitt Lymphoma / metabolism. Herpesvirus 4, Human / physiology. Proto-Oncogene Proteins c-myc / metabolism. Virus Latency / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2002 Oct;8(10):1098-104 [12219084.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11878-83 [12195020.001]
  • [Cites] Virology. 2003 Feb 15;306(2):236-43 [12642097.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4730-5 [12665622.001]
  • [Cites] Nat Rev Immunol. 2003 Oct;3(10):801-12 [14523386.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74 [14603034.001]
  • [Cites] J Virol. 2004 Nov;78(22):12694-7 [15507659.001]
  • [Cites] Gene. 1984 Mar;27(3):279-88 [6329907.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2743-51 [2824192.001]
  • [Cites] J Virol. 1990 May;64(5):2126-34 [2157875.001]
  • [Cites] J Virol. 1990 Jul;64(7):3407-16 [2352328.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] J Virol. 1991 Jan;65(1):415-23 [1845900.001]
  • [Cites] Nature. 1991 Feb 14;349(6310):612-4 [1705663.001]
  • [Cites] EMBO J. 1993 Aug;12(8):3277-86 [8393785.001]
  • [Cites] J Virol. 1994 Sep;68(9):6069-73 [8057484.001]
  • [Cites] Blood. 1995 Jul 15;86(2):659-65 [7605996.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):375-82 [8617212.001]
  • [Cites] J Virol. 1996 Jun;70(6):4179-83 [8648764.001]
  • [Cites] J Virol. 1996 Sep;70(9):5909-15 [8709211.001]
  • [Cites] J Virol. 1996 Aug;70(8):4895-903 [8763992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10411-6 [8816814.001]
  • [Cites] J Virol. 1998 Nov;72(11):9150-6 [9765461.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1651-60 [10022853.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):442-8 [10404101.001]
  • [Cites] J Gen Virol. 2005 Nov;86(Pt 11):3009-19 [16227222.001]
  • [Cites] J Virol. 2005 Aug;79(16):10709-17 [16051863.001]
  • [Cites] J Virol. 1999 Dec;73(12):9827-31 [10559294.001]
  • [Cites] J Virol. 2000 Nov;74(21):10223-8 [11024153.001]
  • [Cites] Immunity. 2000 Oct;13(4):497-506 [11070168.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):420-4 [11208834.001]
  • [Cites] Int J Cancer. 2001 Sep15;93(6):810-6 [11519042.001]
  • [Cites] Cell Death Differ. 2002 Mar;9(3):287-300 [11859411.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):954-65 [11867523.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):764-76 [12360279.001]
  • (PMID = 17001014.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC1595454
  •  go-up   go-down


99. Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, Horowitz MM: Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer; 2010 Jul 15;116(14):3469-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The purpose of the current study was to determine whether the use of hematopoietic stem cell transplantation (HCT) to treat leukemia, lymphoma, or multiple myeloma (MM) differs by race and sex.
  • METHODS: The annual incidence of leukemia, lymphoma, and MM was estimated in the United States in people aged <70 years by race and sex using the Surveillance, Epidemiology, and End Results (SEER) cancer registry between 1997 and 2002 and US census reports for the year 2000.
  • Logistic regression analysis was used to calculate the age-adjusted odds ratio (OR) of receiving HCT for Caucasians versus African Americans and for men versus women.
  • RESULTS: The likelihood of undergoing HCT was found to be higher for Caucasians than for African Americans (OR, 1.40; 95% confidence interval [95% CI], 1.34-1.46).
  • CONCLUSIONS: HCT is more frequently used to treat leukemia, lymphoma, and MM in Caucasians than in African American individuals.
  • African Americans have lower rates of both autologous and allogeneic HCT, indicating that donor availability cannot fully explain the differences.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • [Cites] Obstet Gynecol. 1995 Oct;86(4 Pt 1):486-90 [7675366.001]
  • [Cites] Lancet. 1968 Dec 28;2(7583):1366-9 [4177932.001]
  • [Cites] Med Care. 1995 Nov;33(11):1079-88 [7475418.001]
  • [Cites] Oncol Nurs Forum. 1995 Oct;22(9):1383-91 [8539179.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2644-51 [9215836.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):320-30 [9669815.001]
  • [Cites] Clin Cancer Res. 1995 Feb;1(2):179-84 [9815971.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1231-3 [10519904.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10):805-12 [15545681.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):1045-53 [15685622.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jun;91(3):243-8 [15952057.001]
  • [Cites] N Engl J Med. 2006 Apr 27;354(17):1813-26 [16641398.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2117-21 [17513818.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Mar;14(3):316-22 [18275898.001]
  • [Cites] Urology. 1995 Sep;46(3):346-51 [7660510.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2378-90 [10590381.001]
  • [Cites] BMJ. 2000 Aug 12;321(7258):433-7 [10938056.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 6;94(5):334-57 [11880473.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2106-13 [11966385.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):134-47 [12491515.001]
  • [Cites] Am J Hematol. 2003 Feb;72(2):99-102 [12555212.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3754-60 [14551294.001]
  • [Cites] Lancet. 1968 Dec 28;2(7583):1364-6 [4177931.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jun;34(3):195-8 [7579483.001]
  • (PMID = 20564154.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-14; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / CA076518-14; United States / NHLBI NIH HHS / HL / U01 HL069294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS311623; NLM/ PMC3153958
  •  go-up   go-down


100. Linabery AM, Ross JA: Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. Cancer; 2008 Nov 1;113(9):2575-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results extend those provided by the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program in their detail and interpretation.
  • RESULTS: Five-year survival rates increased significantly overall (1975-1979: 63% vs 1995-1999: 79%; P< .0001) and for nearly all histologic types examined; increases were greatest for ependymoma (+37%; P< .0001) and non-Hodgkin lymphoma (+34%; P< .0001).
  • The largest improvements were noted for acute lymphoblastic leukemia (+19%; P< .0001) and non-Hodgkin lymphoma (+19%; P< .0001).

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2004 Dec;15(10):1027-34 [15801487.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2097-105 [15589307.001]
  • [Cites] Cancer J. 2005 Jul-Aug;11(4):340-54 [16197724.001]
  • [Cites] BMJ. 2005 Dec 3;331(7528):1295 [16299015.001]
  • [Cites] Cancer. 2006 Mar 1;106(5):1162-8 [16429450.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):578-81 [16537719.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1711-42 [16958083.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):177-87 [17219013.001]
  • [Cites] CA Cancer J Clin. 2007 Jul-Aug;57(4):242-55 [17626120.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1070-3 [17943956.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7 Suppl):1074-82 [17943961.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):288-98 [18354417.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1339-45 [12599243.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] Curr Opin Pediatr. 2004 Feb;16(1):9-14 [14758108.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] J Pediatr Oncol Nurs. 2004 May-Jun;21(3):123-7 [15296038.001]
  • [Cites] Biometrics. 1983 Dec;39(4):941-8 [6671129.001]
  • [Cites] JAMA. 1995 Feb 22;273(8):633-7 [7844873.001]
  • [Cites] Epidemiol Rev. 1994;16(2):243-72 [7713179.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):201-7 [8630931.001]
  • [Cites] Int J Cancer. 1996 Dec 11;68(6):759-65 [8980180.001]
  • [Cites] J Adolesc Health. 1997 Dec;21(6):366-73 [9401854.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77 [9731733.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):39-49 [16173961.001]
  • (PMID = 18837040.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA099936-04; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / T32 CA099936-04
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS70883; NLM/ PMC2765225
  •  go-up   go-down






Advertisement